

Updated
September 21, 2009

CURRICULUM VITAE

ROBERTO BOLLI, M.D.

Summary



Dr. Bolli graduated from the University of Perugia (Italy) in 1976. He completed a research Fellowship at the NIH under the mentorship of Stephen E. Epstein (1978–1980) and a clinical Fellowship in Cardiology at Baylor College of Medicine (1981–1983). In 1983 he was appointed Instructor of Medicine and Director of the Experimental Research Laboratory at Baylor College of Medicine, where he rose to the rank of Professor with tenure. In 1994, he became Chief of the Division of Cardiology at the University of Louisville. He is also the Vice Chairman for Research of the Department of Medicine, a Distinguished University Scholar, the Jewish Hospital Distinguished Chair in Cardiology, and the Director of the Institute of Molecular Cardiology at the University of Louisville. Twice at two different institutions (Baylor and University of Louisville), Dr. Bolli developed a leading research program starting from zero.

Dr. Bolli has received the **Physician Scientist Award** of the American College of Chest Physicians (1987), the Pharmacia-Chiron **Young Investigator Award** (1988), the **NIH MERIT Award** (2001–2010), the **Basic Research Prize** of the American Heart Association (AHA) (2001), the **Research Achievement Award** of the International Society for Heart Research (2004), the **Ken Bowman Research Award** of the University of Manitoba (2004), the **Louis and Artur Lucian Award** from McGill University (2004), the **Howard Morgan Award** for Distinguished Achievements in Cardiovascular Research of the International Academy of Cardiovascular Sciences (2005), the **Distinguished Achievement Award** of the AHA (2006), and the **Distinguished Scientist Award** of the AHA (2008). He is a member of the **American Society for Clinical Investigation** and the **Association of American Physicians** and a Foreign Fellow of the **Academy of Sciences of the Royal Society of Canada**. Dr. Bolli has delivered 220 lectures, including three plenary lectures and a State-of-the-Art Lecture at the AHA Sessions, a Landmark Lecture at the XVIIth World Congress of the ISHR (2001), the Keith Reimer Distinguished Lecture of the ISHR (2002), the Robert Berne Distinguished Lecture of the American Physiological Society (2005), and the George E. Brown Memorial Lecture of the AHA (2007).

NIH activities: Dr. Bolli has been a member of the CVB Study Section, the NHLBI Program Project Review Committee, and the NHLBI Advisory Council. **AHA activities:** Besides serving in numerous committees, Dr. Bolli has been Chair of the Pathophysiology Review Committee, of the Council on Basic Cardiovascular Sciences, of the Distinguished Scientist Selection Committee, and of the Council Operations Committee; he has also been a member of the Board of Directors. **International Society for Heart Research:** Dr. Bolli has been Secretary General and Treasurer and is currently President. **Editorial activities:** Dr. Bolli is/has been on the Editorial Board of all major cardiovascular journals, has served as Associate Editor of the *Journal of Molecular and Cellular Cardiology*, and is presently Associate Editor of *Circulation Research* and Guest Editor of *Circulation*. He has been appointed Editor-in-Chief of *Circulation Research*, beginning in July 2009.

Dr. Bolli is PI in several NIH grants, including a MERIT Award and a P01 grant. He has published 311 papers including 211 original articles. Among the original articles, 34 have appeared in *Circulation Research*, 12 in *PNAS*, 7 in *JCI*, and 25 in *Circulation*. Thirty-seven of his papers have been cited more than 100 times, 11 more than 200 times, and 9 more than 300 times. He is first or last author in 66% of the 211 original articles. **Dr. Bolli's Hirsch factor is 77.**

For the past three decades, Dr. Bolli's research has focused on the mechanisms responsible for myocardial ischemia/reperfusion injury and on the development of cardioprotective strategies. His earlier work established a fundamental role of reactive oxygen species in the pathogenesis of myocardial "stunning", a concept that is now accepted as a proven hypothesis. Subsequently, he identified the signal transduction pathways and the cardioprotective genes responsible for the late phase of myocardial "preconditioning", thereby elucidating the molecular basis of this adaptation of the heart to stress. His discovery that the cardioprotection afforded by preconditioning is mediated by two proteins commonly thought to be detrimental (inducible NO synthase and cyclooxygenase-2) has impelled a reassessment of current paradigms regarding these enzymes and has paved the way for developing novel pharmacologic or genetic therapeutic strategies in patients with coronary artery disease. He is currently investigating the use of stem/progenitor cells for repair of infarcted myocardium.



Analysis as of: August 21, 2009

Results found: 607

Sum of the Times Cited : 18,901

Average Citations per Item : 31.14

h-index : 77

Office Address

ACB, Third Floor
550 South Jackson Street
Louisville, Kentucky 40292

Heart and Lung Institute
201 Abraham Flexner Way, Ste. 1001
Louisville, KY 40202

Telephone

Office: (502) 852-1837

FAX

(502) 852-6474

E-mail

rbolli@louisville.edu

Academic Appointments

- 1983-1984 Instructor of Medicine, Baylor College of Medicine, Houston, TX
- 1984-1989 Assistant Professor of Medicine, Baylor College of Medicine, Houston, TX
- 1989-1994 Associate Professor of Medicine, Baylor College of Medicine, Houston, TX
- 1994 Professor of Medicine, Baylor College of Medicine, Houston, TX
- 1994- Professor of Medicine, University of Louisville, Louisville, KY
- 1995- Professor of Physiology and Biophysics, University of Louisville, Louisville, KY
- 1995- Distinguished University Scholar, University of Louisville, Louisville, KY
- 1998- Jewish Hospital Heart and Lung Institute Distinguished Chair in Cardiology
- 2009- Adjunct Professor of Medicine, Johns Hopkins University School of Medicine

Administrative Responsibilities

- 1983-1994 Director, Experimental Research Laboratory, The Methodist Hospital, Houston, TX
- 1985-1986 Co-Director, Coronary Care Unit, Veterans Administration Medical Center, Houston, TX
- 1986-1990 Director, Coronary Care Unit, Veterans Administration Medical Center, Houston, TX
- 1991-1994 Co-Director, Coronary Care Unit, Veterans Administration Medical Center, Houston, TX
- 1986-1990 Chairman, Coronary Care Unit Committee, VA Medical Center, Houston, TX
- 1994- Chief, Division of Cardiology, University of Louisville, Louisville, KY
- 1994- Board of Directors of University Medical Associates, University of Louisville, Louisville, KY
- 1994- Board of Directors of the Jewish Hospital Heart and Lung Institute, Louisville, KY
- 1995-1998 Research Advisory Council, University of Louisville, Louisville, KY
- 2002- Director, Institute of Molecular Cardiology, University of Louisville, Louisville, KY
- 2005- Vice Chairman for Research, Department of Medicine, University of Louisville, Louisville, KY

Hospital Affiliations

- 1995- Active Staff at the Jewish Hospital, University Hospital, and Norton Hospital, Louisville, KY

Honors and Awards

- 1976 Magna Cum Laude, University of Perugia, Perugia, Italy
- 1978-1980 N.I.H. Fogarty Fellowship, September 1978 - December 1980
- 1987-1989 Physician Scientist Award of the American College of Chest Physicians
- 1988 Young Investigator Award "for outstanding work in the field of oxygen free-radical mechanisms in ischemia/reperfusion injury." Organized by the Departments of Physiology and Biochemistry, College of Medicine, University of South Alabama; sponsored by the Pharmacia-Chiron Partnership; presented at the National Meeting on Free Radicals in Biology and Medicine: Ischemia/Reperfusion Injury, Point Clear, AL, March, 1988
- 1990 Keynote speaker at The Oxford International Symposium on "Myocardial Preservation into the 21st Century," Oxford, England, August, 1990
- 1991 American Society for Clinical Investigation
- 1993 Ranked within top 0.3%, NIH R01 HL43151-04 grant application
- 1994 Ranked within top 2.1%, NIH R01 HL55757 grant application
- 1997 Pfizer Visiting Professor, Division of Cardiology and Weinberg Cardiovascular Research Institute, Northwestern University Medical School, March 26-28, 1997
- 1998-2000 Chairman, Clinical and Integrative Cardiovascular Physiology/Pathophysiology I National Peer Review Committee of the AHA
- 1998 Organizer and Chairman of the Scientific Conference of the Council on Circulation of the AHA "Vascular and Myocardial Aspects of Ischemic Heart Disease", Lake Tahoe, NV, February 22-25, 1998

- 1998 Speaker, Plenary Session on "Clinical Applications of Myocardial Preconditioning", 71st Scientific Sessions of the AHA, Dallas, TX, November 9, 1998
- 1998 Ranked within top 0.9%, NIH R01 HL-43151-09 grant application
- 1999 Association of American Physicians
- 1999 Association of University Cardiologists
- 2000 State-of-the-Art Lecturer, Featured Research Session on "Role of Nitric Oxide in Myocardial Ischemia", 73rd Scientific Sessions of the AHA, New Orleans, LA, November 13, 2000
- 2000 Ranked within top 0.2%, NIH R01 HL-55757-06 grant application
- 2000 Organizer and Chairman of the XXII Annual Sessions of the American Section of the ISHR, Louisville, KY, June 14-18, 2000
- 2001 NIH MERIT Award, 2001-2010
- 2001 Basic Research Prize of the American Heart Association
- 2001 Fellow of the International Society for Heart Research
- 2001 Fellow of the American Heart Association (Council on Basic Cardiovascular Sciences)
- 2001 Landmark Lecture, XVII World Congress of the ISHR, Winnipeg, Canada, July 8, 2001
- 2001 Ranked within top 2.4%, NIH R01 HL68088 grant application
- 2002 Fellow of the Cardiovascular Section of the American Physiological Society
- 2002 Keith Reimer Distinguished Lecture of the International Society for Heart Research
- 2002 Landmark Lecture, XXIV Annual Sessions of the North American Section of the ISHR, Madison, WI, July 27, 2002
- 2002 2002 Ranked within top 0.6%, NIH R01 HL-70897 grant application
- 2002 Speaker, Special Session on "New Approaches to Myocardial Ischemia", 75th Scientific Sessions of the AHA, Chicago, IL, November 18, 2002
- 2002 Chairman, Distinguished Scientist Task Force for the Scientific Councils of the AHA
- 2003 Chairman, Reynolds Foundation and AHA Peer Review Committee for the Cardiovascular Clinical Research Center Grants
- 2003-2005 Chairman, Distinguished Scientist Selection Committee of the AHA
- 2003-2006 Chairman, Council on Basic Cardiovascular Sciences of the AHA
- 2003- Chairman, NHLBI Working Group on the Translation of Therapies for Protecting the Heart from Ischemia
- 2003 Keynote Lecture, XXV Annual Sessions of the North American Section of the ISHR, Mystic, CT, June 28, 2003
- 2003-2007 Member, NHLBI Advisory Council
- 2003 Speaker, Special Session on "New Approaches to Protection of Ischemic Myocardium", 76th Scientific Sessions of the AHA, Orlando, FL, November 10, 2003
- 2004 Research Achievement Award of the International Society for Heart Research
- 2004 President's Award for Outstanding Scholarship, Research, and Creative Activity, University of Louisville
- 2004 Ken Bowman Research Award of the Institute of Cardiovascular Sciences, University of Manitoba
- 2004 Louis and Artur Lucian Award for Research in Circulatory Diseases, McGill University
- 2005 Robert Berne Distinguished Lecture of the American Physiological Society
- 2005 Howard Morgan Award for Distinguished Achievements in Cardiovascular Research, International Academy of Cardiovascular Sciences
- 2005- Member, Louis and Artur Lucian Award Selection Committee
- 2005 Faculty, Northwestern University Feinberg School of Medicine Cardiovascular Young Investigators' Forum, Chicago, IL, October 21-22, 2005
- 2005 Speaker, Plenary Session "Translational Science 2005: AHA/ESC: Stem Cell Therapy for Cardiac Regeneration", 78th Scientific Sessions of the AHA, Dallas, TX, November 16, 2005
- 2006-2008 Member, Board of Directors of the American Heart Association
- 2006 MOSAIC (Multicultural Opportunities for Success and Achievement In Our Community) Award from the Jewish Family & Vocational Service, May 11, 2006
- 2006- Foreign Fellow of the Academy of Sciences of the Royal Society of Canada
- 2006 Co-organizer and Co-chair, Third Annual Symposium of the Council on Basic Cardiovascular Sciences of the AHA, Keystone, CO, July 31-August 3, 2006
- 2006 Distinguished Achievement Award of the American Heart Association
- 2006 Faculty, Northwestern University Feinberg School of Medicine Cardiovascular Young Investigators' Forum, Chicago, IL, September 29-30, 2006
- 2006 Michel Mirowski Lecture in Cardiology, Johns Hopkins University

Curriculum Vitae
Roberto Bolli, M.D.

- 2007 Kentucky Institute of Medicine
- 2007 Alpha Omega Alpha Honor Medical Society, University of Louisville
- 2007-2010 President, International Society for Heart Research
- 2007 Faculty, Northwestern University Feinberg School of Medicine Cardiovascular Young Investigators' Forum, Chicago, IL, October 25-27, 2007
- 2007 George E. Brown Memorial Lecture of the American Heart Association
- 2007 Presentation selected for Best of Sessions 2007, 80th Scientific Sessions of the AHA, Orlando, FL, 2007
- 2008 Distinguished Scientist Award of the American Heart Association
- 2008 University of Louisville Favorite Faculty Award
- 2008 Score of 1.10 (corresponding to 0.2% of applications), NIH R24 HL-94373 grant application
- 2008 Faculty, Northwestern University Feinberg School of Medicine Cardiovascular Young Investigators' Forum, Chicago, IL, October 2-5, 2008
- 2008 James T. Willerson Lecture, University of Texas at Houston, October 21, 2008.
- 2008 Lecturer, Gill Heart Institute Cardiovascular Research Day, Lexington, KY, October 24, 2008

Special Recognitions

- 1995- Distinguished University Scholar, University of Louisville, Louisville, KY

Endowments

- 1998- Distinguished Chair in Cardiology, Jewish Hospital Heart and Lung Institute

Named Visiting Professorships

- 1992 British Heart Foundation Visiting Professor, Department of Cardiovascular Research, The Rayne Institute, St. Thomas' Hospital, London, U.K., October, 1992
- 1994 John Walker Moore Visiting Professor, University of Louisville, Louisville, KY, October, 1994
- 1997 Pfizer Visiting Professor, Division of Cardiology and Weinberg Cardiovascular Research Institute, Northwestern University Medical School, March 26-28, 1997
- 2006 Michel Mirowski Visiting Professor, Division of Cardiology, Johns Hopkins University, October 23, 2006
- 2008 James T. Willerson Visiting Professor, University of Texas at Houston, October 21, 2008

Office Positions in Scientific Organizations

American Heart Association

- 1992-1996 Executive Committee of the Council on Circulation
- 1993-1997 Budget Committee of the Council on Circulation
- 1993-1997 Marcus Selection Committee of the Council on Circulation
- 1996-1997 Long Range Planning Committee of the Council on Circulation
- 1998 Nominating Committee for the Cardiovascular Research Prize of the Council on Circulation 1998 Co-Chairman of the Scientific Conference of the Council on Circulation "Vascular and Myocardial Aspects of Ischemic Heart Disease", Lake Tahoe, NV, February 22-25, 1998
- 1998-2000 National Research Committee
- 1998-2000 Chairman, Clinical and Integrative Cardiovascular Physiology/Pathophysiology I National Peer Review Committee
- 1998-2000 Executive Committee of the Council on Circulation
- 1999- Nominating Committee of the Council on Basic Cardiovascular Sciences
- 2000- 2003 Program Committee of the Council on Basic Cardiovascular Sciences
- 2000-2002 Communications Committee and Co-Manager of the Web Site, Council on Basic Cardiovascular Sciences
- 2001-2002 AHA Science Classification Task Force
- 2001-2003 Vice Chairman, Council on Basic Cardiovascular Sciences
- 2002 Member Benefits Task Force
- 2002 Chairman, Distinguished Scientist Task Force for the Scientific Councils of the AHA
- 2002-2003 Strategically Focused Research Task Force
- 2002-2005 Committee on Scientific Sessions Program (at-large member)
- 2002-2005 Chairman, Distinguished Scientist Selection Committee

Curriculum Vitae
Roberto Bolli, M.D.

2003 Chairman, Reynolds Foundation and AHA Peer Review Committee for the Cardiovascular Clinical Research Center Grants

2003- Science Advisory and Coordinating Committee

2003-2006 Chairman, Council on Basic Cardiovascular Sciences

2003 Advertising Agency Selection Committee

2004-2006 Chairman, Council Operations Committee

2004- 2006 Advocacy Coordinating Committee

2004- 2006 Strategic Planning Task Force

2005-2006 International Mentoring Task Force

2005-2006 Future of Scientific Sessions Task Force

2006 AHA Fellow Task Force

2006-2008 Board of Directors

2006 Chair, Working Group on Biomedical Research Environment, AHA Research Strategic Planning Retreat, June 19-20, 2006

2006-2007 Research Strategic Planning Task Force

2008-2009 Nominating and Awards Committee

2009- Editor-in-Chief, *Circulation Research*

International Society for Heart Research

1994-1998 Council Member, ISHR - American Section

1995 Selection Committee for the Award for Young Investigators, ISHR-American Section

1997 Selection Committee for the Pharmacia and Upjohn Award for Young Investigators, ISHR-American Section

1998 Selection Committee for the Richard Bing Award

1998-2004 Secretary General of the ISHR

2000 Chairman, XXII Annual Sessions of the ISHR - American Section, Louisville, KY, June 14-18, 2000

2001-2004 Treasurer of the ISHR

2004-2007 President-Elect of the ISHR

2007-2010 President of the ISHR

2006- Leader, Focus Group on Cell Therapy, North American Section of the ISHR

Other

1998- Institutional Representative of the ASCI for the University of Louisville

American Physiological Society

2004-2007 Industry-Foundations Liaison Committee of the Cardiovascular Section of the American Physiological Society

Associate Editor/Editor

1999-2009 Associate Editor, *Circulation Research*

1999-2007 Associate Editor, *Journal of Molecular and Cellular Cardiology*

2004-2007 Guest Editor, *Circulation*

2008 Senior Guest Editor, *Circulation* (January-December)

2008- Associate Editor, AHA Learning Library

2009- Editor-in-Chief, *Circulation Research*

Editorial Boards

1992-1999 *Circulation Research*

1991-1998 *American Journal of Physiology: Heart and Circulatory Physiology*

2006- *American Journal of Physiology: Heart and Circulatory Physiology*

1999 *American Journal of Physiology*, Member of the Board of Medical Editors

1991-1993 *Circulation*

2001-2004 *Circulation*

1987-1991 *Journal of the American College of Cardiology*

1989-1999 *Journal of Molecular and Cellular Cardiology*

1992-1996 *Cardiovascular Research*

1994- *Basic Research in Cardiology*

1992- *Cardiovascular Drugs and Therapy*

1991-1996 *American Heart Journal*

Curriculum Vitae
Roberto Bolli, M.D.

1995-	<i>Experimental and Clinical Cardiology</i>
1995-	<i>Dialogues in Cardiovascular Medicine</i>
1998-	<i>Heart News and Views</i>
2001-2005	<i>Journal of Thoracic and Cardiovascular Anesthesia</i>
2001-	<i>Korean Journal of Cardiovascular Diseases</i>
2002-	<i>Coronary Artery Disease</i>
2003-	<i>Journal of Cardiovascular Medicine</i>
2004-	<i>Heart Lung and Circulation</i>
2006-	<i>Minerva Cardioangiologica</i>
2008-	<i>Texas Heart Institute Journal</i>
2009	<i>Circulation Journal</i> (Member of the International Advisory Board)

Reviewer for

Science
American Heart Journal
American Journal of Cardiology
American Journal of Physiology
Cardiovascular Drugs & Therapy
Circulation
Circulation Research
Coronary Artery Disease
Free Radical Research Communications
Journal of Cardiovascular Pharmacology
Journal of Clinical Investigation
Journal of Molecular and Cellular Cardiology
Journal of Pharmacology and Experimental Therapeutics
Journal of the American College of Cardiology
Life Sciences
New England Journal of Medicine
Journal of Thoracic and Cardiovascular Anesthesia

Review Panels

National Institutes of Health

1990-1992	<i>Ad Hoc</i> Member, Cardiovascular & Renal Study Section
1992-1996	Regular Member, Cardiovascular & Renal Study Section
1998	Cardiovascular Sciences Special Emphasis Panel, April, 1998
1999	Special Emphasis Panel to Review SCOR in Ischemic Heart Disease Grant Applications, June, 1999
2000	<i>Ad Hoc</i> Member, Cardiovascular Study Section (CVA)
2000-2003	NHLBI Program Project Review Committee HLBP
2007-	Protocol Review Committee, NHLBI Cardiovascular Cell Therapy Research Network (CCTRN)
2008	<i>Ad Hoc</i> Member, Myocardial Ischemia and Metabolism (MIM) Study Section

American Heart Association

1998-2000	Chairman, Clinical and Integrative Cardiovascular Physiology/Pathophysiology I National Peer Review Committee
1988-1994	Central Research Review Committee of the AHA Texas Affiliate
1993-1997	Marcus Selection Committee of the Council on Circulation
1999	Reynolds Foundation and AHA Peer Review Committee for the Cardiovascular Clinical Research Program
1991-	Abstract Grader for the 1991, 1992, 1993, 1994, 1995, 1996, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, and 2008 Scientific Sessions of the AHA
2003	Chairman, Reynolds Foundation and AHA Peer Review Committee for the Cardiovascular Clinical Research Center Grants

Other

1990-	<i>Ad Hoc</i> Reviewer, VA Merit Review grant applications
1990	Abstract Grader for the Scientific Sessions of the ACC

Curriculum Vitae**Roberto Bolli, M.D.**

- 1991 Abstract Grader for the Scientific Sessions of the ACC
 1995-1999 Scientific Review Committee, Jewish Hospital Foundation, Louisville, KY
 2005 Faculty, Northwestern University Feinberg School of Medicine Cardiovascular Young Investigators' Forum, Chicago, IL, October 21-22, 2005.
 2006 Faculty, Northwestern University Feinberg School of Medicine Cardiovascular Young Investigators' Forum, Chicago, IL, September 28-October 1, 2006
 2007 Faculty, Northwestern University Feinberg School of Medicine Cardiovascular Young Investigators' Forum, Chicago, IL, October 25-27, 2007
 2008 Faculty, Northwestern University Feinberg School of Medicine Cardiovascular Young Investigators' Forum, Chicago, IL, October 2-5, 2008

Advisory Activities for the NIH

- 1995 Special Emphasis Panel (SEP), January, 1995
 1996 Special Emphasis Panel (SEP) on Integrative Research, April, 1996
 2001 Member, Cardiovascular Sciences Study Section Boundaries Team, October 31 – November 2, 2001
 2003 Member, SPARK II Conference, January 20, 2003
 2003 Chairman, NHLBI Working Group on the Translation of Therapies for Protecting the Heart from Ischemia
 2003-2007 Member, NHLBI Advisory Council
 2006 NHLBI Working Group on Regenerative Medicine

Steering Committees

- 2000-2003 EXPEDITION Trial

Professional Societies

- American Society for Clinical Investigation, 1991
- Association of American Physicians, 1999
- American College of Cardiology, Fellow, 1987
- Association of University Cardiologists, 1999
- Council on Clinical Cardiology of the AHA, Fellow, 1985
- Council on Circulation of the AHA, Fellow
- Council on Basic Cardiovascular Sciences of the AHA, Fellow
- International Society for Heart Research, 1984
- American College of Physicians, Fellow, 1988
- American Physiological Society
- American Federation for Clinical Research
- The Oxygen Society
- International Academy of Cardiovascular Sciences, Fellow, 1997
- Academy of Sciences of the Royal Society of Canada, Foreign Fellow, 2006-
- Kentucky Institute of Medicine, 2007-

Major Research Interests

- Protection of Ischemic Myocardium
- Mechanisms of Ischemia and Reperfusion Injury
- Role of Oxygen-Derived Free Radicals in Ischemia and Reperfusion
- Postischemic Myocardial Dysfunction ("Stunned Myocardium")
- Ischemic Preconditioning
- Gene Therapy
- Stem/Progenitor Cells
- Cell Therapy for Cardiac Repair After Infarction

Clinical Responsibilities

Attending in the Coronary Care Unit

Patents

1. ***VSEL Stem Cells and Methods of Isolating and Using the Same.*** Number PCT/US06/042780; priority filing date: December 8, 2005. (Pending)

2. Provisional patent application for VSEs and the cardiac application: ***Therapeutic Transplantation of VSEL Stem Cells for Cardiac Repair Following Myocardial Infarction***. Priority filing date: October 30, 2007. (Serial number not yet available.)

Research Support

(Total direct costs of grants in which Dr. Bolli is/was Principal Investigator: \$47,782,003)

(i) Active

1. Title: "Oxygen Radicals and Cardiac Adaptations to Ischemia"
Agency: NIH
Role: Principal Investigator
Dates: 2005-2010
Cost: Annual direct cost \$363,550; total direct cost \$1,940,008
Grant #: MERIT Award R37 HL-55757-06 (percentile score: 0.2)
2. Title: "Mechanisms of Cardioprotection"
Agency: NIH
Role: Principal Investigator
Dates: 2003-2008
Cost: Annual direct cost \$359,127; total direct cost \$1,989,958
Grant #: R01 HL-70897-01 (percentile score: 0.6)
3. Title: "Hematopoietic Stem Cell Therapy for Myocardial Regeneration"
Agency: NIH
Role: Principal Investigator
Dates: 2004-2008
Cost: Annual direct cost \$316,101; total direct cost \$1,357,617
Grant #: 1 R01 HL076794-01
4. Title: P01 Grant "Protection of Ischemic Myocardium"
Agency: NIH
Role: Principal Investigator
Dates: 2005-2010
Cost: Annual direct cost \$1,656,251; total direct cost \$8,790,181
Grant #: P01 HL-78825 (score: 143)
5. Title: "Center for Excellence in Diabetes and Obesity Research"
Agency: NIH
Role: Co-Principal Investigator
Dates: 2008-2013
Cost: Annual direct cost \$1,996,871; total direct cost \$11,596,871
Grant #: 1 P20 RR024489

(ii) Pending

1. Title: R24 Grant "Preclinical Consortium to Facilitate Translation of Cardioprotective Therapies"
Agency: NIH
Role: Principal Investigator
Dates: 2009-2013
Cost: Annual direct cost \$1,550,000; total direct cost \$12,500,000
Grant #: R24 HL-94373 (score: 1.10 [0.2 percentile])

(iii) Completed

1. Title: "Role of Oxygen Free Radicals in Postischemic Dysfunction"
Agency: American Heart Association, Texas Affiliate

- Role: Principal Investigator (no Co-investigators)
Dates: 1985-1989
Cost: Total direct cost \$110,000
Grant #: Three grants: Nos. 85G/225, 87R/171, and 88R/171
2. Title: Physician Scientist Award
Agency: American College of Chest Physicians
Role: Principal Investigator (no Co-investigators)
Dates: 1987-1989
Cost: Total direct cost \$70,000
3. Title: "Role of Oxygen Radicals in Postischemic Dysfunction"
Agency: NIH
Role: Principal Investigator
Dates: 1989-1992
Cost: Total direct cost \$563,000
Grant #: R01 HL-43151 01-03
4. Title: "Role of Oxygen Radicals in Postischemic Dysfunction"
Agency: NIH
Role: Principal Investigator
Dates: 1993-1997
Cost: Annual direct cost \$188,021; total direct cost \$1,220,880
Grant #: R01 HL-43151 04-08 (percentile score: 0.3)
5. Title: "Oxygen Radicals and Cardiac Adaptations to Ischemia"
Agency: NIH
Role: Principal Investigator
Dates: 1994-1999
Cost: Annual direct cost \$229,677; total direct cost \$1,250,846
Grant #: R01 HL-55757 (percentile score: 2.1)
6. Title: "Oxygen Radicals and Cardiac Adaptations to Ischemia"
Agency: NIH
Role: Principal Investigator
Dates: 2000-2004
Cost: Annual direct cost \$286,445; total direct cost \$1,578,500
Grant #: MERIT Award R37 HL-55757-06 (percentile score: 0.2)
7. Title: "SCOR in Heart Failure"
Agency: NIH
Role: Principal Investigator in project "Pathogenesis and Response to Therapy of Clinical and Experimental Acute Cardiac Failure Secondary to Postischemic Dysfunction"
Dates: 1990-1994
Cost: Annual direct cost \$115,425; total direct cost \$589,000
Grant #: P50 HL-42267
8. Title: "Role of Oxygen Radicals in Postischemic Dysfunction"
Agency: NIH
Role: Principal Investigator
Dates: 1998-2003
Cost: Annual direct cost \$244,631; total direct cost \$1,336,476
Grant #: R01 HL-43151 09-13 (percentile score: 0.9)
9. Title: "Community Health Promotions Programs"
Agency: CDC
Role: Principal Investigator

- Dates: 2004-2006
Cost: Total direct cost \$1,247,665
Grant #: H75/CCH424252
10. Title: "Molecular Basis of Preconditioning"
Agency: NIH
Role: Principal Investigator
Dates: 2001-2006
Cost: Annual direct cost \$287,890; total direct cost \$1,641,001
Grant #: R01 HL-68088-01 (percentile score: 2.4)

(iii) TRAINING GRANTS

1. Title: MRC Fellowship
Agency: Medical Research Council of Canada
Role: Mentor for Michael Hill, Ph.D.
Dates: 1998-2001
2. Title: Research Fellowship
Agency: Heart and Stroke Foundation of Canada
Role: Mentor for Michael Hill, Ph.D.
Dates: 1998-2000
(declined due to overlap with the MRC Fellowship)
3. Title: Research Fellowship
Agency: American Heart Association, KY Affiliate
Role: Mentor for Yiru Guo, M.D.
Dates: 1998-1999
4. Title: Research Fellowship
Agency: American Heart Association, Ohio Valley Affiliate
Role: Mentor for Yiru Guo, M.D.
Dates: 1999-2000
5. Title: Research Fellowship
Agency: American Heart Association, Ohio Valley Affiliate
Role: Mentor for Qianhong Li, M.D., Ph.D.
Dates: 2000-2001
6. Title: Research Fellowship
Agency: American Heart Association, Ohio Valley Affiliate
Role: Mentor for Ken Shinmura, M.D., Ph.D.
Dates: 2000-2001
7. Title: Research Fellowship
Agency: American Heart Association, Ohio Valley Affiliate
Role: Mentor for Adam Stein, M.D.
Dates: 2003-2005
8. Title: Fellow-to-Faculty Transition Award
Agency: American Heart Association, National Award
Role: Mentor for Adam Stein, M.D.
Dates: 2005-2010

Publications

Hirsch Factor (8/24/09): 77

Total of 311 papers published or in press (not including abstracts, case reports, letters)

(*Articles cited more than 100 times are marked with an asterisk.)

Bibliometric Analysis (updated 7/09/09)

Analysis of Citations

Articles Cited				
100-199 times	200-299 times	300-399 times	400-699 times	> 700 times
37	11	5	3	1
Articles Cited 100 – 199 times		Original report 19, 25, 26, 28 34, 41, 71, 72, 74, 78, 83, 84, 85, 89, 92, 93, 94, 98, 99, 100, 104, 107, 111, 120, 129, 137, 148, 163, 171		
		Review 10, 11, 13, 15, 21, 27, 32, 39		
Articles Cited 200 – 299 times		Original Report 35, 40, 51, 58, 90, 106, 115, 130		
		Review 5, 19, 26		
Articles Cited 300 – 399 times		Original Report 20, 45, 88		
		Review 14, 25		
Articles Cited 400 – 699 times		Original Report 39, 46		
		Review 22		
Articles Cited > 700 times		Review 9		

Analysis of Journals (original reports only)				
JCI	PNAS	Circ Res	Circulation	Am J Physiol
7	12	34	25	41

Analysis of Authorship (original reports only)			
First Author	Second Author	Last Author	First, Second or Last Author
28 (13%)	16 (8%)	110(52%)	154 (73%)

Publications: (i) ORIGINAL REPORTS

1981

1. **Bolli R**, Goldstein RE, Davenport N, Epstein SE. Influence of sulfinpyrazone and naproxen on infarct size in the dog. *Am J Cardiol* 47:841-847, 1981.

1983

2. Sheehan FH, Goldstein RE, **Bolli R**, Epstein SE. The effects of nitroglycerin-methoxamine combination on infarct size in conscious dogs. *Am Heart J* 105:37-43, 1983.
3. **Bolli R**, Magro SA, Wyndham CRC. Concealed antidromic re-entrance during rapid atrial pacing in the Wolff-Parkinson-White syndrome. *Pacing Clin Electrophysiol* 6:185-191, 1983.
4. **Bolli R**, Brandon TA, Luck JC, Miller RR, Entman ML. Deleterious effects of incomplete myocardial reperfusion on ventricular arrhythmias. *J Am Coll Cardiol* 1:1111-1118, 1983.
5. **Bolli R**, Davenport NJ, Goldstein RE, Epstein SE. Myocardial proteolysis during acute myocardial ischemia. *Cardiovasc Res* 17:274-281, 1983.
6. Cannon RO, Butany JW, McManus BM, Speir E, Kravitz AB, **Bolli R**, Ferrans VJ. Early degradation of collagen after acute myocardial infarction in the rat. *Am J Cardiol* 52:390-395, 1983.

7. **Bolli R**, Cannon RO, Speir E, Goldstein RE, Epstein SE. Role of cellular proteinases in acute myocardial infarction. I. Proteolysis in nonischemic and ischemic rat myocardium and the effects of antipain, leupeptin, pepstatin and chymostatin administered *in vivo*. *J Am Coll Cardiol* 2:671-680, 1983.
8. **Bolli R**, Cannon RO, Speir E, Goldstein RE, Epstein SE. Role of cellular proteinases in acute myocardial infarction. II. Influence of *in vivo* suppression of myocardial proteolysis by antipain, leupeptin and pepstatin on myocardial infarct size in the rat. *J Am Coll Cardiol* 2:681-688, 1983.
9. **Bolli R**, Brandon TA, Fisher DJ, Miller RR. Beneficial effects of the alpha-adrenergic antagonist nicergoline during acute myocardial ischemia and reperfusion in the dog. *Am Heart J* 106:1014-1023, 1983.

1984

10. Davenport N, Goldstein RE, **Bolli R**, Epstein SE. Blood flow to infarct and surviving myocardium: Implications regarding the action of verapamil on the acutely ischemic dog heart. *J Am Coll Cardiol* 3:956-965, 1984.
11. Ware JA, Horak JK, **Bolli R**, Mathur VS, Massumi GA, Solis RT. Intravascular microaggregation and *in vitro* platelet aggregation in coronary artery disease. *Thromb Res* 34:9-18, 1984.
12. **Bolli R**, Brandon TA, Ware JA, Weilbaecher DG, Mace ML Jr. Platelet-mediated thrombosis in stenosed canine coronary arteries: Inhibition by nicergoline, a platelet-active alpha-adrenergic antagonist. *J Am Coll Cardiol* 3:1417-1426, 1984.
13. **Bolli R**, Kuo LC, Roberts R. Influence of acute arterial hypertension on myocardial infarct size in dogs without left ventricular hypertrophy. *J Am Coll Cardiol* 4:522-528, 1984.
14. **Bolli R**, Fisher DJ, Taylor AA, Young JB, Miller RR. Effect of alpha-adrenergic blockade on arrhythmias induced by acute myocardial ischemia and reperfusion in the dog. *J Mol Cell Cardiol* 16:1101-1117, 1984.
15. Fernandez GC, Chapman AJ Jr, **Bolli R**, Rose SD, O'Meara ME, Luck JC, Young JB. Gonococcal endocarditis: A case series demonstrating modern presentation of an old disease. *Am Heart J* 108:1326-1334, 1984.

1985

16. **Bolli R**, Brandon TA, Weilbaecher DG, Mace ML Influence of alpha-adrenergic blockade on platelet-mediated thrombosis in stenosed canine coronary arteries. *Cardiovasc Res* 19:146-154, 1985.
17. Cannon RO, Rodriguez ER, Speir E, Yamaguchi M, Butany J, McManus BM, **Bolli R**, Ferrans VJ. Effect of ibuprofen on the healing phase of experimental myocardial infarction in the rat. *Am J Cardiol* 55:1609-1613, 1985.
18. Hartley CJ, Litowitz H, Lewis RM, **Bolli R**, Entman ML. Quantification of layer-by-layer myocardial thickening with an epicardial ultrasonic transducer. *Med & Biol Engr & Comp* 23, Suppl 2:1300-1301, 1985.
- *19. **Bolli R**, Zhu WX, Myers ML, Hartley CJ, Roberts R. Beta-adrenergic stimulation reverses postischemic myocardial dysfunction without producing subsequent functional deterioration. *Am J Cardiol* 56:964-968, 1985.
Citations since 1989: 193

- *20. Myers ML, **Bolli R**, Lekich RF, Hartley CJ, Roberts R. Enhancement of recovery of myocardial function by oxygen free-radical scavengers after reversible regional ischemia. *Circulation* 72:915-921, 1985. **Citations since 1989: 318**

1986

21. **Bolli R**, Fisher DJ, Entman ML Factors that determine the occurrence of arrhythmias during acute myocardial ischemia. *Am Heart J* 111:261-270, 1986.
22. **Bolli R**, Myers ML, Zhu WX, Roberts R. Disparity of reperfusion arrhythmias after reversible myocardial ischemia in open chest and conscious dogs. *J Am Coll Cardiol* 7:1047-1056, 1986.
23. Rokey R, Verani MS, **Bolli R**, Kuo LC, Ford JJ, Wendt RE, Schneiders NJ, Bryan RN, Roberts R. Myocardial infarct size quantification by MR imaging early after coronary artery occlusion in dogs. *Radiology* 158:771-774, 1986.
24. Zhu WX, Myers ML, Hartley CJ, Roberts R, **Bolli R**. Validation of a single crystal for measurement of transmural and epicardial thickening. *Am J Physiol* 251:H1045-H1055, 1986.

- *25. Myers ML, **Bolli R**, Lekich RF, Hartley CJ, Roberts R. N-2-mercaptopropionyl glycine improves recovery of myocardial function after reversible regional ischemia. *J Am Coll Cardiol* 8:1161-1168, 1986. **Citations since 1989: 111**

1987

- *26. Charlat ML, O'Neill PG, Egan JM, Abernethy DR, Michael LH, Myers ML, Roberts R, **Bolli R**. Evidence for a pathogenetic role of xanthine oxidase in the "stunned" myocardium. *Am J Physiol* 252:H566-H577, 1987. **Citations: 126**
27. Kuo LC, **Bolli R**, Thornby J, Roberts R, Verani MS. Effects of exercise tolerance, age and gender on the specificity of radionuclide angiography: Sequential ejection fraction analysis during multistage exercise. *Am Heart J* 113:1180-1189, 1987.
- *28. **Bolli R**, Zhu WX, Hartley CJ, Michael LH, Repine J, Hess ML, Kukreja RC, Roberts R. Attenuation of dysfunction in the postischemic "stunned" myocardium by dimethylthiourea. *Circulation* 76:458-468, 1987. **Citations: 195**
29. Verani MS, **Bolli R**, Tadros S, Myers ML, Neto SB, Jain A, Phillips LA, Roberts R. Dissociation between global and regional systolic and diastolic ventricular function during coronary occlusion and reperfusion. *Am Heart J* 114:687-695, 1987.
30. O'Neill PG, Charlat ML, Kim H-S, Pocius J, Michael LH, Hartley CJ, Roberts R, **Bolli R**. Lipoxygenase inhibitor nafazatom fails to attenuate postischemic ventricular dysfunction. *Cardiovasc Res* 21:755-760, 1987.
31. Zoghbi WA, Charlat ML, **Bolli R**, Kopelen H, Hartley CJ, Roberts R, Quinones MA. End-systolic radius to thickness ratio: An echocardiographic index of regional performance during reversible myocardial ischemia in the conscious dog. *J Am Coll Cardiol* 10:1113-1121, 1987.
- *32. **Bolli R**, Patel BS, Zhu WX, O'Neill PG, Charlat ML, Roberts R. The iron chelator desferrioxamine attenuates postischemic ventricular dysfunction. *Am J Physiol* 253:H1372-H1380, 1987. **Citations: 166**
33. Bennett WR, Yawn DH, Migliore PJ, Young JB, Raizner AE, Roberts R, **Bolli R**. Activation of the complement system by recombinant tissue plasminogen activator. *J Am Coll Cardiol* 10:627-632, 1987.
34. Mahmarian JJ, Verani M, Hohmann T, Hill R, Thornton BC, **Bolli R**, Young JB, Roberts R. The hemodynamic effects of sotalol and quinidine: Analysis by use of rest and exercise gated radionuclide angiography. *Circulation* 76:324-331, 1987

1988

- *35. **Bolli R**, Zhu WX, Thornby JI, O'Neill PG, Roberts R. Time-course and determinants of recovery of function after reversible ischemia in conscious dogs. *Am J Physiol* 254:H102-H114, 1988. **Citations: 244**
36. **Bolli R**, Patel B. Factors that determine the occurrence of reperfusion arrhythmias. *Am Heart J* 115:20-29, 1988.
37. Zoghbi WA, Charlat ML, **Bolli R**, Zhu WX, Hartley CJ, Quinones MA. Quantitative assessment of left ventricular wall motion by two-dimensional echocardiography: Validation during reversible ischemia in the conscious dog. *J Am Coll Cardiol* 11:851-860, 1988.
38. Patel B, Hartley CJ, Suignard LJ, Chelly JE, Jeroudi MO, Rabinovitz RS, Litowitz H, Charlat ML, O'Neill PG, Noon GP, Short HD, Roberts R, **Bolli R**. Ultrasonic sensors for measuring regional ventricular function. *Microsensors and Catheter-Based Imaging Technology*, West AI, Ed., SPIE, Bellingham, WA, pp. 87-91, 1988.
- *39. **Bolli R**, Patel BS, Jeroudi MO, Lai EK, McCay PB. Demonstration of free radical generation in "stunned" myocardium of intact dogs with the use of the spin trap alpha-phenyl N-tert-butyl nitron. *J Clin Invest* 82:476-485, 1988. **Citations: 592**
- *40. Verani MS, Jeroudi MO, Mahmarian JJ, Boyce TM, Borges-Neto S, Patel B, **Bolli R**. Quantification of myocardial infarction during coronary occlusion and myocardial salvage after reperfusion using cardiac imaging with technetium-99m hexakis 2-methoxyisobutyl isonitrite. *J Am Coll Cardiol* 12:1573-1581, 1988. **Citations: 202**

1989

- *41. Charlat ML, O'Neill PG, Hartley CJ, Roberts R, **Bolli R**. Prolonged abnormalities of left ventricular diastolic wall thinning in the "stunned" myocardium in conscious dogs: time-course and relation to systolic function. *J Am Coll Cardiol* 13:185-194, 1989. **Citations: 103**
42. Hartley CJ, Rabinovitz RS, Lee HS, Chelly JE, Noon GP, **Bolli R**. Postoperative measurements of ventricular function in man using an implantable ultrasonic sensor. *Catheter-Based Sensing and Imaging Technology* 1068:53-58, 1989.
43. O'Neill PG, Charlat ML, Michael LH, Roberts R, **Bolli R**. Influence of neutrophil depletion on myocardial function and flow after reversible ischemia. *Am J Physiol* 256:H341-H351, 1989.
44. Cheirif J, Zoghbi WA, **Bolli R**, O'Neill PG, Hoyt BD, Quinones MA. Assessment of regional myocardial perfusion by contrast echocardiography. II. Detection of changes in transmural and subendocardial reperfusion during dipyridamole-induced hyperemia in a model of critical coronary stenosis. *J Am Coll Cardiol* 14:1555-1565, 1989.
- *45. **Bolli R**, Jeroudi MO, Patel BS, DuBose CM, Lai EK, Roberts R, McCay PB. Direct evidence that oxygen-derived free radicals contribute to posts ischemic myocardial dysfunction in the intact dog. *Proc Natl Acad Sci USA* 86:4695-4699, 1989. **Citations: 322**
- *46. **Bolli R**, Jeroudi MO, Patel BS, Aruoma OI, Halliwell B, Lai EK, McCay PB. Marked reduction of free radical generation and contractile dysfunction by antioxidant therapy begun at the time of reperfusion: Evidence that myocardial "stunning" is a manifestation of reperfusion injury. *Circ Res* 65:607-622, 1989. **Citations: 486**
47. **Bolli R**, Patel BS, Hartley CJ, Thornby JI, Jeroudi MO, Roberts R. Nonuniform transmural recovery of contractile function in the "stunned" myocardium. *Am J Physiol* 257:H375-H385, 1989.

1990

48. **Bolli R**, Hartley CJ, Chelly JE, Patel BS, Rabinovitz RS, Jeroudi MO, Roberts R, Noon G. An accurate non-traumatic ultrasonic method to monitor myocardial wall thickening in patients undergoing cardiac surgery. *J Am Coll Cardiol* 15:1055-1065, 1990.
49. Michael LH, Zhang Z, Hartley CJ, **Bolli R**, Taylor AA, Entman ML. Thromboxane B2 in cardiac lymph: effect of superoxide dismutase and catalase during myocardial ischemia and reperfusion. *Circ Res* 66:1040-1044, 1990.
50. Patel BS, Jeroudi MO, O'Neill PG, Roberts R, **Bolli R**. Effect of human recombinant superoxide dismutase on canine myocardial infarction. *Am J Physiol* 258:H369-H380, 1990.
- *51. **Bolli R**, Triana JF, Jeroudi MO. Prolonged impairment of coronary vasodilation after reversible ischemia: Evidence for microvascular "stunning." *Circ Res* 67:332-343, 1990. **Citations: 208**
52. Jeroudi MO, Triana JF, Patel BS, **Bolli R**. Effect of superoxide dismutase and catalase, given separately, on myocardial "stunning." *Am J Physiol* 259:H889-H901, 1990.
53. O'Neill PG, Puleo PR, **Bolli R**, Rokey R. Return of atrial function following electrical conversion of atrial dysrhythmias. *Am Heart J* 120:353-359, 1990.
54. Puppo A, Cecchini R, Aruoma OI, **Bolli R**, Halliwell B. Scavenging of hypochlorous acid and of myoglobin-derived oxidants by the cardioprotective agent mercaptopropionylglycine. *Free Radic Res Commun* 10:371-381, 1990.
55. **Bolli R**, Patel BS, Jeroudi MO, Li XY, Triana JF, Lai EK, McCay PB. Iron-mediated radical reactions upon reperfusion contribute to myocardial "stunning". *Am J Physiol* 259:H1901-H1911, 1990.

1991

56. Rokey R, Vick GW, **Bolli R**, Lewandowski D, Johnston DL. Assessment of experimental pericardial effusion using nuclear magnetic resonance imaging techniques. *Am Heart J* 121:1161-1169, 1991.
57. Hartley CJ, Litowitz H, Rabinovitz RS, Zhu WX, Chelly JE, Michael LH, **Bolli R**. An ultrasonic method for measuring tissue displacement: Technical details and validation for measuring myocardial thickening. *IEEE Trans Biomed Eng* 38:735-747, 1991.

- *58. Habib GB, Heibig J, Forman SA, Brown BG, Roberts R, Terrin ML, **Bolli R.** Influence of coronary collateral vessels on myocardial infarct size in humans: Results of phase I thrombolysis in myocardial infarction (TIMI) trial. *Circulation* 83:739-746, 1991. **Citations: 210**
59. Triana JF, **Bolli R.** Decreased flow reserve in "stunned" myocardium after a 10-minute coronary occlusion. *Am J Physiol* 261:H793-H804, 1991.
60. Triana JF, Li XY, Jamaluddin U, Thornby JI, **Bolli R.** Postischemic myocardial "stunning": Identification of major differences between the open-chest and the conscious dog and evaluation of the oxygen radical hypothesis in the conscious dog. *Circ Res* 69:731-747, 1991.

1992

61. Cheirif JB, Desir RM, **Bolli R,** Mahmorian JJ, Zoghbi WA, Verani MS, Quinones MA. Relation of perfusion defects observed with myocardial contrast echocardiography to the severity of coronary stenosis: Correlation with thallium-201 single-photon emission tomography. *J Am Coll Cardiol* 19:1343-1349, 1992.

1993

62. Li XY, Sun JZ, Bradamante S, Piccinini F, **Bolli R.** Effects of the spin trap alpha-phenyl N-tert-butyl nitron on myocardial function and flow: A dose-response study in the open-chest dog and in the isolated rat heart. *Free Radic Biol Med* 14:277-285, 1993.
63. Sun JZ, Li XY, Sporn MB, Schneider MD, Roberts R, **Bolli R.** Effect of transforming growth factor-beta 1 on myocardial stunning in the intact dog. *J Mol Cell Cardiol* 25:379-386, 1993.
64. Li XY, McCay PB, Zughuib M, Jeroudi MO, Triana JF, **Bolli R.** Demonstration of free radical generation in the "stunned" myocardium in the conscious dog and identification of major differences between conscious and open-chest dogs. *J Clin Invest* 92:1025-1041, 1993.
65. Sun JZ, Kaur H, Halliwell B, Li XY, **Bolli R.** Use of aromatic hydroxylation of phenylalanine to measure production of hydroxyl radicals after myocardial ischemia *in vivo*: Direct evidence for a pathogenetic role of the hydroxyl radical in myocardial stunning. *Circ Res* 73:534-549, 1993.
66. Sekili S, McCay PB, Li XY, Zughuib M, Sun JZ, Tang XL, Thornby JI, **Bolli R.** Direct evidence that the hydroxyl radical plays a pathogenetic role in myocardial "stunning" in the conscious dog and that stunning can be markedly attenuated without subsequent adverse effects. *Circ Res* 73:705-723, 1993.
67. Zughuib ME, Abd-Elfattah AS, Jeroudi MO, Sun JZ, Sekili S, Tang XL, **Bolli R.** Augmentation of endogenous adenosine attenuates myocardial "stunning" independently of coronary flow or hemodynamic effects. *Circulation* 88:2359-2369, 1993.

1994

68. Desir RM, Cheirif JB, **Bolli R,** Zoghbi WA, Hoyt BD, Quinones MA. Assessment of regional myocardial perfusion with myocardial contrast echocardiography in a canine model of varying degrees of coronary stenosis. *Am Heart J* 127:56-63, 1994.
69. Zughuib ME, Tang XL, Schleman M, Jeroudi MO, **Bolli R.** Beneficial effects of MDL 74,405, a cardioselective water soluble alpha-tocopherol analogue, on the recovery of function of stunned myocardium in intact dogs. *Cardiovasc Res* 28:235-241, 1994.
70. Jeroudi MO, Cheirif J, Habib G, **Bolli R.** Prolonged wall motion abnormalities after an episode of chest pain at rest: Evidence for the occurrence of myocardial "stunning" in unstable angina. *Am Heart J* 127:1241-1250, 1994.
- *71. French BA, Mazur W, Geske RS, **Bolli R.** Direct *in vivo* gene transfer into porcine myocardium using replication-deficient adenoviral vectors. *Circulation* 90:2414-2424, 1994. **Citations: 130**
- *72. Galli M, Marcassa C, **Bolli R,** Giannuzzi P, Temporelli PL, Imparato A, Silva Orrego PL, Giubbini R, Giordano A, Tavazzi L. Spontaneous delayed recovery of perfusion and contraction after the first 5 weeks after anterior infarction: Evidence for the presence of hibernating myocardium in the infarcted area. *Circulation* 90:1386-1397, 1994. **Citations: 101**

1995

73. Sekili S, Jeroudi MO, Tang XL, Zughuib M, Sun JZ, **Bolli R**. Effect of adenosine on myocardial "stunning" in the dog. *Circ Res* 76:82-94, 1995.
- *74. Sun JZ, Tang XL, Knowlton AA, Park SW, Qiu Y, **Bolli R**. Late preconditioning against myocardial stunning: An endogenous protective mechanism that confers resistance to postischemic dysfunction 24 hours after brief ischemia in conscious pigs. *J Clin Invest* 95:388-403, 1995. **Citations: 170**
75. Tang XL, McCay PB, Sun JZ, Hartley CJ, Schleman M, **Bolli R**. Inhibitory effect of a hydrophilic alpha-tocopherol analogue, MDL 74,405, on generation of free radicals in stunned myocardium in dogs. *Free Radic Res* 22:293-302, 1995.
76. **Bolli R**, Zughuib, M, Li XY, Tang XL, Sun JZ, Triana JF, McCay P. Recurrent ischemia in the canine heart causes recurrent bursts of free radical production that have a cumulative effect on contractile function: A pathophysiological basis for chronic myocardial "stunning". *J Clin Invest* 96:1066-1084, 1995.
77. Tang XL, Kaur H, Sun JZ, Qiu Y, Park SW, Schleman M, Halliwell B, **Bolli R**. Effect of the hydrophilic alpha-tocopherol analog MDL 74,405 on the detection of hydroxyl radicals in stunned myocardium in dogs. *Am Heart J* 130:940-948, 1995.

1996

- *78. Sun JZ, Tang XL, Park SW, Qiu Y, Turrens JF, **Bolli R**. Evidence for an essential role of reactive oxygen species in the genesis of late preconditioning against myocardial stunning in conscious pigs. *J Clin Invest* 97:562-576, 1996. **Citations: 155**
79. Park SW, Tang XL, Qiu Y, Sun JZ, **Bolli R**. Nisoldipine attenuates myocardial stunning induced by multiple coronary occlusions in conscious pigs and this effect is independent of changes in hemodynamics or coronary blood flow. *J Mol Cell Cardiol* 28:655-666, 1996 (Featured article).
80. Tang XL, Qiu Y, Park SW, Sun JZ, Kalya A, **Bolli R**. Time-course of late preconditioning against myocardial stunning in conscious pigs. *Circ Res* 79:424-434, 1996.
81. Wallis G, Brackett D, Lerner M, Kotake Y, **Bolli R**, McCay PB. *In vivo* spin trapping of nitric oxide generated in the small intestine, liver, and kidney during the development of endotoxemia: a time-course study. *Shock* 6:274-278, 1996.

1997

82. Qiu Y, Tang XL, Park SW, Sun JZ, Kalya A, **Bolli R**. The early and late phases of ischemic preconditioning: A comparative analysis of their effects on infarct size, myocardial stunning, and arrhythmias in conscious pigs undergoing a 40-min coronary occlusion. *Circ Res* 80:730-742, 1997.
- *83. Auchampach JA, Rizvi A, Qiu Y, Tang X-L, Maldonado C, Teschner S, **Bolli R**. Selective activation of A₃ adenosine receptors with N⁶-(3-iodobenzyl)adenosine-5'-N-methyluronamide protects against myocardial stunning and infarction without hemodynamic changes in conscious rabbits. *Circ Res* 80:800-809, 1997. **Citations: 121**
- *84. Leeser MA, Stoddard M, Ahmed M, Broadbent J, **Bolli R**. Preconditioning of human myocardium with adenosine during coronary angioplasty. *Circulation* 95:2500-2507, 1997. **Citations: 176**
- *85. **Bolli R**, Bhatti ZA, Tang X-L, Qiu Y, Zhang Q, Guo Y, Jadoon AK. Evidence that late preconditioning against myocardial stunning in conscious rabbits is triggered by the generation of nitric oxide. *Circ Res* 81:42-52, 1997. **Citations: 190**
86. Tang X-L, Qiu Y, Turrens JF, Sun J-Z, **Bolli R**. Late preconditioning against stunning is not mediated by increased antioxidant defenses in conscious pigs. *Am J Physiol* 273:H1651-H1657, 1997.
87. Maldonado C, Qiu Y, Tang X-L, Cohen MV, Auchampach J, **Bolli R**. Role of adenosine receptors in late preconditioning against myocardial stunning in conscious rabbits. *Am J Physiol* 42:H1324-H1332, 1997.
- *88. Ping P, Zhang J, Qiu Y, Tang X-L, Manchikalapudi S, Cao X, **Bolli R**. Ischemic preconditioning induces selective translocation of protein kinase C isoforms ϵ and η in the heart of conscious rabbits without subcellular redistribution of total protein kinase C activity. *Circ Res* 81:404-414, 1997. **Citations: 331**

89. Qiu Y, Rizvi A, Tang X-L, Manchikalapudi S, Takano H, Jadoon AK, Wu W-J, **Bolli R**. Nitric oxide triggers late preconditioning against myocardial infarction in conscious rabbits. *Am J Physiol* 273:H2931-H2936, 1997. **Citations: 111**
- *90. **Bolli R**, Manchikalapudi S, Tang X-L, Takano H, Qiu Y, Guo Y, Zhang Q, Jadoon AK. The protective effect of late preconditioning against myocardial stunning in conscious rabbits is mediated by nitric oxide synthase: Evidence that nitric oxide acts both as a trigger and as a mediator of the late phase of ischemic preconditioning. *Circ Res* 81:1094-1107, 1997. **Citations: 216**

1998

91. Li Q, Murphree SS, Willer SS, **Bolli R**, French BA. Gene therapy with bilirubin-UDP-glucuronosyltransferase in the Gunn rat model of Crigler-Najjar syndrome type 1. *Hum Gene Ther* 9:497-505, 1998.
- *92. Qiu Y, Ping P, Tang X-L, Manchikalapudi S, Rizvi A, Zhang J, Takano H, Wu W-J, Teschner S, **Bolli R**. Direct evidence that protein kinase C plays an essential role in the development of late preconditioning against myocardial stunning in conscious rabbits and that ϵ is the isoform involved. *J Clin Invest* 101:2182-2198, 1998. **Citations: 117**
- *93. Takano H, Tang X-L, Qiu Y, Guo Y, **Bolli R**. Nitric oxide donors induce late preconditioning against myocardial stunning and infarction in conscious rabbits via an antioxidant-sensitive mechanism. *Circ Res* 83:73-84, 1998. **Citations: 152**
- *94. Takano H, Manchikalapudi S, Tang X-L, Qiu Y, Rizvi A, Jadoon AK, Zhang Q, **Bolli R**. Nitric oxide synthase is the mediator of late preconditioning against myocardial infarction in conscious rabbits. *Circulation* 98:441-449, 1998. **Citations: 166**
95. Guo Y, Wu W-J, Qiu Y, Tang X-L, Yang Z, **Bolli R**. Demonstration of an early and a late phase of ischemic preconditioning in mice. *Am J Physiol* 275:H1375-H1387, 1998.
96. Li Q, **Bolli R**, Qiu Y, Tang X-L, Murphree SS, French BA. Gene therapy with extracellular superoxide dismutase attenuates myocardial stunning in conscious rabbits. *Circulation* 98:1438-1448, 1998.
97. Marcassa C, Galli M, **Bolli R**, Temporelli PL, Campini R, Giannuzzi P. Heterogeneous fate of perfusion and contraction after anterior wall acute myocardial infarction and effects on left ventricular remodeling. *Am J Cardiol* 82:1457-1462, 1998.

1999

- *98. Ping P, Zhang J, Cao X, Li RCX, Kong D, Tang XL, Qiu Y, Manchikalapudi S, Auchampach J, Black RG, **Bolli R**. PKC-dependent activation of p44/p42 MAPKs during myocardial ischemia-reperfusion in conscious rabbits. *Am J Physiol* 276:H1468-H1481, 1999. **Citations 110**
- *99. Ping P, Takano H, Zhang J, Tang X-L, Qiu Y, Li RCX, Banerjee S, Dawn B, Balafonova Z, **Bolli R**. Isoform-selective activation of protein kinase C by nitric oxide in the heart of conscious rabbits: A signaling mechanism for both nitric oxide-induced and ischemia-induced preconditioning. *Circ Res* 84:587-604, 1999 (with cover photograph). **Citations: 166**
- *100. Xuan Y-T, Tang X-L, Banerjee S, Takano H, Li J-J, Qiu Y, Han H, Li, R, **Bolli R**. Nuclear factor κ B plays an essential role in the genesis of the late phase of ischemic preconditioning in conscious rabbits. *Circ Res* 84:1095-1109, 1999. **Citations: 191**
101. Ping P, Zhang J, Huang S, Cao X, Tang X-L, Li RC, Zheng Y-T, Qiu Y, Clerk A, Sugden P, Han JH, **Bolli R**. PKC ϵ -dependent activation of p46 and p54 JNKs during ischemic preconditioning in conscious rabbits. *Am J Physiol* 277:H1771-H1785, 1999.
102. Leeser MA, Stoddard MF, Manchikalapudi S, **Bolli R**. Bradykinin-induced preconditioning in patients undergoing coronary angioplasty. *J Am Coll Cardiol* 34:639-650, 1999.
103. Rizvi A, Tang X-L, Qiu Y, Xuan Y-T, Takano H, Jadoon AK, **Bolli R**. Increased protein synthesis is necessary for the development of late preconditioning against myocardial stunning in conscious rabbits. *Am J Physiol* 277:H874-H884, 1999.

- *104. Mahaffey KW, Puma JA, Barbagelata NA, DiCarli MF, Leeser MA, Browne KF, Eisenberg PR, **Bolli R**, Casas AC, Molina-Viamonte V, Orlandi C, Blevins R, Gibbons RJ, Califf RM, Granger CB. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: Results of a multicenter, randomized, placebo-controlled trial. The Acute Myocardial Infarction Study of Adenosine (AMISTAD) trial. *J Am Coll Cardiol* 34:1711-1720, 1999. **Citations: 185**
105. Jones WK, Flaherty MP, Tang X-L, Takano H, Qiu Y, Banerjee S, Smith T, **Bolli R**. Ischemic preconditioning increases iNOS transcript levels in conscious rabbits via a nitric oxide-dependent mechanism. *J Mol Cell Cardiol* 31:1469-1481, 1999.
- *106. Guo Y, Jones WK, Xuan Y-T, Tang X-L, Bao W, Wu W-J, Han H, Laubach VE, Ping P, Yang Z, Qiu Y, **Bolli R**. The late phase of ischemic preconditioning is abrogated by targeted disruption of the iNOS gene. *Proc Natl Acad Sci USA* 96:11507-11512, 1999. **Citations: 237**
- *107. Ping P, Zhang J, Zheng YT, Li RC, Dawn B, Tang X-L, Takano H, Balafanova Z, **Bolli R**. Demonstration of selective, PKC-dependent activation of Src and Lck tyrosine kinases during ischemic preconditioning in conscious rabbits. *Circ Res* 85:542-550, 1999. **Citations: 109**
108. Shinmura K, Tang X-L, Takano H, Hill M, **Bolli R**. Nitric oxide donors attenuate myocardial stunning in conscious rabbits. *Am J Physiol* 277:H2495-H2503, 1999.
109. Banerjee S, Tang X-L, Qiu Y, Takano H, Manchikalapudi S, Dawn B, Shirk G, **Bolli R**. Nitroglycerin induces late preconditioning against myocardial stunning via a protein kinase C dependent pathway. *Am J Physiol* 277:H2488-H2494, 1999.
110. Dawn B, Xuan Y-T, Qiu Y, Takano H, Tang X-L, Ping P, Banerjee S, Hill M, **Bolli R**. Bifunctional role of protein tyrosine kinases in late preconditioning against myocardial stunning in conscious rabbits. *Circ Res* 85:1154-1163, 1999.

2000

- *111. Takeishi Y, Ping P, **Bolli R**, Kirkpatrick DL, Hoit BD, Walsh RA. Transgenic overexpression of constitutively active protein kinase C ϵ causes concentric cardiac hypertrophy. *Circ Res* 86:1218-1223, 2000. **Citations 128**
112. Li RCX, Ping P, Zhang Z, Wead WB, Cao X, Gao J, Zheng Y, Huang S, Han J-H, **Bolli R**. PKC ϵ modulates NF- κ B and AP-1 via mitogen activated protein kinases in adult rabbit cardiomyocytes. *Am J Physiol* 279:H1679-H1689, 2000.
113. Xuan Y-T, Tang X-L, Qiu Y, Banerjee S, Takano H, Han H, **Bolli R**. Biphasic response of cardiac NO synthase to ischemic preconditioning in conscious rabbits. *Am J Physiol* 279:H2360-H2371, 2000.
114. Takano H, Tang X-L, **Bolli R**. Differential role of K_{ATP} channels in late preconditioning against myocardial stunning and infarction in rabbits. *Am J Physiol* 279:H2350-H2359, 2000.
- *115. Shinmura K, Tang X-L, Wang Y, Xuan Y-T, Liu S-Q, Takano H, Bhatnagar A, **Bolli R**. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. *Proc Natl Acad Sci USA* 97:10197-10202, 2000. **Citations: 214**
116. Takano H, Tang X-L, **Bolli R**. Late preconditioning enhances recovery of myocardial function after infarction in conscious rabbits. *Am J Physiol* 279:H2372-H2381, 2000.
117. Guo Y, Bao W, Wu W-J, Shinmura K, Tang X-L, **Bolli R**. Evidence for an essential role of cyclooxygenase-2 as a mediator of the late phase of ischemic preconditioning in mice. *Basic Res Cardiol* 95:480-485, 2000.

2001

118. Pass JM, Zheng Y, Wead WB, Zhang J, Li RC, **Bolli R**, Ping P. PKC ϵ activation induces dichotomous cardiac phenotypes and modulates PKC ϵ -RACK interactions and RACK expression. *Am J Physiol* 280:H946-H955, 2001.
119. Dawn B, Xuan Y-T, Marian M, Flaherty MP, Murphree SS, Smith TL, **Bolli R**, Jones WK. Cardiac-specific abrogation of NF- κ B activation in mice by transdominant expression of a mutant I κ B α . *J Mol Cell Cardiol* 33:161-173, 2001.
120. Ping P, Zhang J, Pierce WM, **Bolli R**. Functional proteomic analysis of PKC ϵ signaling complexes associated with cardioprotection. *Circ Res* 88:59-62, 2001. **Citations: 121**

121. Takano H, **Bolli R**, Black RG, Jr., Kodani E, Tang X-L, Yang Z, Bhattacharya S, Auchampach JA. A₁ or A₃ adenosine receptors induce late preconditioning against infarction in conscious rabbits by different mechanisms. *Circ Res* 88:520-528, 2001.
122. Li Q, **Bolli R**, Qiu Y, Tang X-L, Guo Y, French BA. Gene therapy with extracellular superoxide dismutase protects conscious rabbits against myocardial infarction. *Circulation* 103:1893-1898, 2001.
123. Guo Y, **Bolli R**, Bao W, Wu W-J, Black R, Murphree S, Salvatore C, Jacobson M, Auchampach JA. Targeted deletion of the A₃ adenosine receptor confers resistance to myocardial ischemic injury and does not prevent early preconditioning. *J Mol Cell Cardiol* 33:825-830, 2001.
124. Leeser MA, Stoddard MF, Dawn B, Jasti VG, Masden R, **Bolli R**. Delayed preconditioning-mimetic action of nitroglycerin in patients undergoing coronary angioplasty. *Circulation* 103:2935-2941, 2001.
125. Kodani E, **Bolli R**, Tang X-L, Auchampach JA. The protection of IB-MECA against myocardial stunning in conscious rabbits is not mediated by the A₁ adenosine receptor. *Basic Res Cardiol* 96:487-496, 2001.
126. Hill M, Takano H, Tang X-L, Kodani E, Shirk G, **Bolli R**. Nitroglycerin induces late preconditioning against myocardial infarction in conscious rabbits despite development of nitrate tolerance. *Circulation* 104:694-699, 2001.
127. Kodani E, Shinmura K, Xuan Y-T, Takano H, Auchampach JA, Tang X-L, **Bolli R**. Cyclooxygenase-2 does not mediate late preconditioning against infarction induced by adenosine A₁ or A₃ receptors. *Am J Physiol* 281:H959-H968, 2001.
128. Vondriska T, Zhang J, Song C, Tang X-L, Cao X, Baines C, Pass J, Wang S, **Bolli R**, Ping P. Protein kinase C ϵ -Src modules direct signal transduction in nitric oxide-induced cardioprotection: Complex formation as a means for cardioprotective signaling. *Circ Res* 88:1306-1313, 2001.
- *129. Xuan Y-T, Guo Y, Han H, Zhu Y, **Bolli R**. An essential role of the JAK-STAT pathway in ischemic preconditioning. *Proc Natl Acad Sci USA* 98:9050-9055, 2001. **Citations: 109**
- *130. Chen L, Hahn H, Wu G, Chen C-H, Liron T, Schechtman D, Cavallaro G, Banci L, Guo Y, **Bolli R**, Dorn G, Mochly-Rosen D. Opposing cardioprotective actions and parallel hypertrophic effect of δ and ϵ PKC. *Proc Natl Acad Sci U S A* 98:11114-11119, 2001. **Citations: 229**
131. Pass J, Gao J, Jones WK, Wead WB, Wu J, Zhang J, Baines C, **Bolli R**, Zheng YT, Joshua I, Ping P. Enhanced PKC β II translocation and PKC β II-RACK1 interactions in PKC ϵ -induced cardiac hypertrophy and failure: A role for RACK1. *Am J Physiol* 281:H2500-H2510, 2001.

2002

132. Tang X-L, Takano H, Rizvi A, Turrens J, Qiu Y, Wu W-J, Zhang Q, **Bolli R**. Oxidant species trigger late preconditioning against myocardial stunning in conscious rabbits. *Am J Physiol* 282:H281-H291, 2002.
133. Cross HR, Murphy E, **Bolli R**, Ping P, Steenbergen C. Expression of activated PKC epsilon protects the ischemic heart, without attenuating ischemic H⁺ production. *J Mol Cell Cardiol* 34:361-367, 2002.
134. Wang Y, Guo Y, Zhang S, Wu W-J, Wang J, Bao W, **Bolli R**. Ischemic preconditioning upregulates inducible nitric oxide synthase in cardiac myocytes. *J Mol Cell Cardiol* 34:5-15, 2002 (with cover photograph).
135. Shinmura K, Xuan YT, Tang XL, Kodani E, Han H, Zhu Y, **Bolli R**. Inducible nitric oxide synthase modulates cyclooxygenase-2 activity in the heart of conscious rabbits during the late phase of ischemic preconditioning. *Circ Res* 90:602-608, 2002.
136. Ping P, Song C, Zhang J, Guo Y, Cao X, Li RCX, Wu W, Vondriska TM, Pass JM, Tang XL, Pierce W, **Bolli R**. Formation of PKCepsilon-Lck signaling modules confers cardioprotection. *J Clin Invest* 109:499-507, 2002.
- *137. Baines PC, Zhang J, Wang GW, Zheng YT, Xiu JX, Cardwell EM, **Bolli R**, Ping P. Mitochondrial PKC ϵ and MAPK form signaling modules in the murine heart. *Circ Res* 90:390-397, 2002. **Citations: 185**
138. Balafanova Z, **Bolli R**, Zhang J, Zheng Y, Pass JM, Bhatnagar A, Tang XL, Wang O, Cardwell E, Ping P. Nitric oxide induces nitration of PKC epsilon, facilitating PKC epsilon translocation via enhanced PKCepsilon-RACK2 interactions: A novel mechanism of NO-triggered activation of PKC epsilon. *J Biol Chem* 277:15021-15027, 2002.

139. Kodani E, Xuan YT, Takano H, Shinmura K, Tang XL, **Bolli R**. Role of cyclic guanosine monophosphate in late preconditioning in conscious rabbits. *Circulation* 105:3046-3052, 2002.
140. Dawn B, Takano H, Tang XL, Kodani E, Banerjee S, Rezazadeh A, Qiu Y, **Bolli R**. Role of Src protein tyrosine kinases in late preconditioning against myocardial infarction. *Am J Physiol* 283:H549-H556, 2002.
141. Black RG Jr, Guo Y, Ge ZD, Murphree SS, Prabhu SD, Jones WK, **Bolli R**, Auchampach JA. Gene dosage-dependent effects of cardiac-specific overexpression of the A3 adenosine receptor. *Circ Res* 91:165-172, 2002.
142. Kodani E, Xuan YT, Shinmura K, Takano H, Tang XL, **Bolli R**. δ -opioid receptor-induced late preconditioning is mediated by cyclooxygenase-2 in conscious rabbits. *Am J Physiol* 283:H1943-H1957, 2002.
143. Shinmura K, **Bolli R**, Liu SQ, Tang XL, Kodani E, Xuan YT, Srivastava S, Bhatnagar A. Aldose reductase is an obligatory mediator of the late phase of ischemic preconditioning. *Circ Res* 91:240-246, 2002.
144. Shinmura K, Nagai M, Tamaki K, Tani M, **Bolli R**. Cyclooxygenase-2-derived prostacyclin mediates opioid-induced late phase of preconditioning in isolated perfused rat hearts. *Am J Physiol* 283:H2534-H2543, 2002.

2003

145. Sasaki N, Murata M, Guo Y, Jo SH, Ohler A, Akao M, O'Rourke B, Xiao RP, **Bolli R**, Marbán E. MCC-134, a single pharmacophore, opens surface ATP-sensitive potassium channels, blocks mitochondrial ATP-sensitive potassium channels, and suppresses preconditioning. *Circulation* 107:1183-1188, 2003.
146. Leesar MA, Abdul-Baki T, Akkus NI, Sharma A, Kannan T, **Bolli R**. Use of fractional flow reserve versus stress perfusion scintigraphy after unstable angina. Effect on duration of hospitalization, cost, procedural characteristics, and clinical outcome. *J Am Coll Cardiol* 41:1115-1121, 2003.
147. Shinmura K, Kodani E, Xuan YT, Dawn B, Tang XL, **Bolli R**. Effect of aspirin on late preconditioning against myocardial stunning in conscious rabbits. *J Am Coll Cardiol* 41:1183-1194, 2003.
148. Baines CP, Song CX, Zheng YT, Wang GW, Zhang J, Wang OL, Guo Y, **Bolli R**, Cardwell EM, Ping P. Protein kinase C epsilon interacts with and inhibits the permeability transition pore in cardiac mitochondria. *Circ Res* 92:873-880, 2003. **Citations: 150**
149. Li QH, Guo Y, Xuan YT, Lowenstein CJ, Stevenson SC, Prabhu SD, Wu W-J, Zhu Y, **Bolli R**. Gene therapy with inducible nitric oxide synthase protects against myocardial infarction via a cyclooxygenase-2-dependent mechanism. *Circ Res* 92:741-748, 2003.
150. Xuan YT, Guo Y, Zhu Y, Han H, Langenbach R, Dawn B, **Bolli R**. Mechanism of cyclooxygenase-2 upregulation in late preconditioning. *J Mol Cell Cardiol* 35:525-527, 2003.
151. Leesar MA, Stoddard MF, Xuan YT, Tang XL, **Bolli R**. Nonelectrocardiographic evidence that both ischemic preconditioning and adenosine preconditioning exist in humans. *J Am Coll Cardiol* 6;42:437-445, 2003.
152. Boyce SW, Bartels C, **Bolli R**, Chaitman B, Chen JC, Chi E, Jessel A, Kereiakes D, Knight J, Thulin L, Theroux P. Impact of sodium-hydrogen exchange inhibition by cariporide on death or myocardial infarction in high-risk CABG surgery patients: Results of the CABG surgery cohort of the GUARDIAN study. *J Thorac Cardiovasc Surg* 126:420-427, 2003.
153. Zhang J, Ping P, Vondriska TM, Tang XL, Wang GW, Cardwell EM, **Bolli R**. Cardioprotection involves activation of NF- κ B via PKC-dependent tyrosine and serine phosphorylation of I κ B α . *Am J Physiol* 285:H1753-H1758, 2003.
154. Tang XL, Kodani E, Takano H, Hill M, Shinmura K, Vondriska TM, Ping P, **Bolli R**. Protein tyrosine kinase signaling is necessary for NO donor-induced late preconditioning against myocardial stunning. *Am J Physiol* 284:H1441-H1448, 2003.

2004

155. Shinmura K, Nagai M, Tamaki K, **Bolli R**. Gender and aging do not impair opioid-induced late preconditioning in rats. *Basic Res Cardiol* 99:46-55, 2004.
156. Tang XL, Xuan YT, Zhu Y, Shirk G, **Bolli R**. Nicorandil induces late preconditioning against myocardial infarction in conscious rabbits. *Am J Physiol* 286:H1273-H1280, 2004.
157. Guo Y, Stein AB, Wu WJ, Tan W, Zhu X, Li QH, Dawn B, Motterlini R, **Bolli R**. Administration of a CO-releasing molecule at the time of reperfusion reduces infarct size *in vivo*. *Am J Physiol* 286: H1649-H1653, 2004.

158. Dawn B, Guo Y, Rezazadeh A, Wang O-L, Stein AB, Hunt G, Varma J, Xuan Y-T, Wu W-J, Wei T, Zhu X, **Bolli R**. Tumor necrosis factor-alpha does not modulate ischemia/reperfusion injury in naïve myocardium but is essential for the development of late preconditioning. *J Mol Cell Cardiol* 37:51-61, 2004.
159. Wang Y, Kodani E, Wang J, Zhang SX, Takano H, Tang X-L, **Bolli R**. Cardioprotection during the final stage (72 h) of the late phase of ischemic preconditioning is mediated by neuronal NO synthase in concert with cyclooxygenase-2. *Circ Res* 95:84-91, 2004.
160. Dawn B, Xuan YT, Guo Y, Rezazadeh A, Stein AB, Hunt G, Wu WJ, Tan W, **Bolli R**. IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2. *Cardiovasc Res* 64:61-71, 2004.
161. Zhang J, Ping P, Wang G-W, Ming L, Dawn P, Tang X-L, **Bolli R**, Vondriska T. Bmx, a member of the Tec family of non-receptor tyrosine kinases, is a novel participant in pharmacological cardioprotection. *Am J Physiol* 56:2364-2366, 2004.
162. Tang XL, Stein AB, Shirk G, **Bolli R**. Hypercholesterolemia blunts NO donor-induced late preconditioning against myocardial infarction in conscious rabbits. *Basic Res Cardiol* 99:395-403, 2004.
- *163. Kucia M, Dawn B, Hunt G, Guo Y, Wysoczynski M, Majka M, Ratajczak J, Rezzoug F, Ildstad ST, **Bolli R**,* Ratajczak MZ*. Cells expressing early cardiac markers reside in the bone marrow and are mobilized into the peripheral blood following myocardial infarction. *Circ Res* 95:1191-1199, 2004. (*Drs.Bolli and Ratajczak are co-last authors on this manuscript.) **Citations: 115**

2005

164. Shinmura K, Tamaki K, Sato T, Ishida H, **Bolli R**. Prostacyclin attenuates oxidative damage of myocytes by opening mitochondrial ATP-sensitive K⁺ channels via the EP3 receptor. *Am J Physiol* 288:H2093-H2101, 2005.
165. Stein AB, Guo Y, Tan W, Wu WJ, Zhu X, Li Q, Luo C, Dawn B, Johnson TR, Motterlini R, **Bolli R**. Administration of a CO-releasing molecule induces late preconditioning against myocardial infarction. *J Mol Cell Cardiol* 38:127-134, 2005.
166. Martindale JJ, Wall JA, Martinez-Longoria DM, Aryal P, Rockman HA, Guo Y, **Bolli R**, Glembotski CC. Over-expression of MKK6 in the heart improves functional recovery from ischemia *in vitro* and protects against myocardial infarction *in vivo*. *J Biol Chem* 280:669-676, 2005.
167. Dawn B, Stein AB, Urbanek K, Rota M, Whang B, Rastaldo R, Torella D, Tang X-L, Rezazadeh A, Kajstura J, Leri A, Hunt G, Varma J, Prabhu SD, Anversa P, **Bolli R**. Cardiac stem cells delivered intravascularly traverse the vessel barrier, regenerate infarcted myocardium, and improve cardiac function. *Proc Natl Acad Sci U.S.A.* 102:3766-3771, 2005.
168. Jneid, H, Chandra, M, Alshaher, M, Hornung, CA, Tang, XL, Leesar, M, **Bolli, R**. Delayed preconditioning-mimetic actions of nitroglycerin in patients undergoing exercise tolerance tests. *Circulation* 111: 2565-2571, 2005.
169. Syed FM, Hahn HS, Odley A, Guo Y, Vallejo JG, Lynch RA, Mann DL, **Bolli R**, Dorn GW. Proapoptotic effects of caspase-1/ICE dominate in myocardial ischemia. *Circ Res* 96:1103-3309,2005.
170. Shinmura K, Tamaki K, **Bolli, R**. Short-term caloric restriction improves ischemic tolerance independent of opening of ATP-sensitive K⁺ channels in both young and aged hearts. *J Mol Cell Cardiol* 39:285-296, 2005.
- *171. Urbanek K, Torella D, Sheikh F, Nurzynska D, Silvestri F, Beltrami C, Beltrami A, Bussani R, Quaini F, **Bolli R**, Leri A, Kajstura J, Anversa P. Myocardial regeneration by activation of multipotent cardiac stem cells in ischemic heart failure. *Proc Nat Acad Sci* 102:8692-8697, 2005. **Citations: 107**
172. Guo Y, Stein A, Wu W, Zhu X, Tan W, Li Q, **Bolli, R**. Late preconditioning induced by NO donors, adenosine A₁ receptor agonists, and delta₁-opioid receptor agonists is mediated by iNOS. *Am J Physiol* 289:H2251-H2257, 2005.
173. Jneid H, Leesar M, **Bolli, R**. Cardiac preconditioning during percutaneous coronary interventions: A post-hoc analysis and literature review. *Cardiovasc Drugs Ther* 19:211-217, 2005.

174. Tang XL, Takano H, Xuan YT, Sato H, Kodani E, Dawn B, Zhu Y, Shirk GA, Wu WJ, **Bolli R**. Hypercholesterolemia abrogates late preconditioning via a tetrahydrobiopterin-dependent mechanism in conscious rabbits. *Circulation* 112:2149-2156, 2005.
175. Xuan YT, Guo Y, Zhu Y, Wang OL, Rokosh G, Messing RO, **Bolli R**. Role of the PKC ϵ -Raf-1-MEK-1/2-p44/42 MAPK signaling cascade in the activation of STAT1 and STAT3 and induction of COX-2 following ischemic preconditioning. *Circulation* 112:1971-1978, 2005.

2006

176. Li Q, Guo Y, Tan W, Stein AB, Dawn B, Wu W-J, Zhu X, Lu X, Xu X, Siddiqui T, Tiwari S, **Bolli R**. Gene therapy with inducible nitric oxide synthase provides long-term protection against myocardial infarction without adverse functional consequences. *Am J Physiol* 290:H584-H589, 2006.
177. Dawn B, Guo Y, Rezazadeh A, Huang Y, Stein A, Hunt G, Tiwari S, Varma J, Gu Y, Prabhu S, Kajstura J, Anversa P, Ildstad S, **Bolli R**. Postinfarct cytokine therapy regenerates cardiac tissue and improves left ventricular function. *Circ Res* 98:1098-1105, 2006.
178. Urbanek K, Cesselli D, Rota M, Nascimbene A, De Angelis A, Hosoda T, Bearzi C, Boni A, **Bolli R**, Kajstura J, Anversa P, Leri A.. Stem cell niches in the adult mouse heart. *Proc Nat Acad Sci* 103:9226-9231, 2006.
179. Tang XL, Sato H, Tiwari S, Dawn B, Bi Q, Li Q, Shirk G, Bolli R. Cardioprotection by postconditioning in conscious rats is limited to coronary occlusions <45 minutes. *Am J Physiol* 291:H2308-2317, 2006.
180. Zuba-Surma EK, Abdel-Latif A, Case J, Tiwari S, Hunt G, Kucia M, Vincent RJ, Ranjan S, Ratajczak MZ, Srour EF, **Bolli R**, Dawn B. SCA-1 expression is associated with decreased cardiomyogenic differentiation potential of skeletal muscle-derived adult primitive cells. *J Mol Cell Cardiol* 41:650-660, 2006.

2007

181. Stein AB, Tiwari S, Thomas P, Hunt G, Levent C, Stoddard MF, Tang XL, **Bolli R**, Dawn B. Effect of anesthesia on echocardiographic assessment of left ventricular structure and function in rats. *Basic Res Cardiol* 102:28-41, 2007.
182. Leesar M, Jneid H, Tang XL, **Bolli R**. Pretreatment with intracoronary enalaprilat protects human myocardium during percutaneous coronary angioplasty. *J Am Coll Cardiol* 49:1607-10, 2007.
183. Abdel-Latif A, **Bolli R**, Teyjeh IM, Montori VM, Perin EC, Hornung CA, Zuba-Surma EK, Al-Mallah M, Dawn B. Adult bone marrow-derived cells for cardiac repair: A systematic review and meta-analysis. *Arch Int Med* 167: 989-997, 2007.
184. Benjamin IJ, Guo Y, Srinivasan S, Boudina S, Taylor R, Rajasekaran N, Gottlieb R, Wawrousek E, Abel ED, **Bolli R**. CRYAB and HSPB2 deficiency alters cardiac metabolism and paradoxically confers protection against myocardial ischemia in aging mice. *Am J Physiol* 293:H3201-3209, 2007.
185. Stein A, **Bolli R**, Guo Y, Wang OL, Tan W, Wu W, Zhu X, Zhu Y, Xuan YT. The late phase of ischemic preconditioning induces a prosurvival genetic program that results in marked attenuation of apoptosis. *J Mol Cell Cardiol* 42:1075-1085, 2007.
186. Xuan YT, Guo Y, Zhu Y, Wang OL, Rokosh G, **Bolli R**. eNOS plays an obligatory role in the late phase of ischemic preconditioning by activating the PKC ϵ -p44/42 MAPK-pSer-STAT1/3 Pathway. *Circulation* 116:535-544, 2007.
187. Hu X, Dai S, Wu W, Tan W, Zhu X, Mu J, Guo Y, **Bolli R**, Rokosh G. SDF-1a confers protection against myocardial ischemia/reperfusion injury: Role of the cardiac SDF-1a-CXCR4 axis. *Circulation* 116:654-663, 2007.
188. Li Q, Guo Y, Tan W, Ou Q, Wu W, Sturza D, Dawn B, Hunt G, Cui C, **Bolli R**. The cardioprotection afforded by inducible nitric oxide synthase gene therapy is mediated by COX-2 via an NF- κ B –dependent pathway. *Circulation* 116:1577-1584, 2007.
189. Shinmura K, Tamaki K, Saito K, Nakano Y, Tobe T, **Bolli R**. Cardioprotective effects of short-term caloric restriction are mediated by adiponectin via activation of AMP-activated protein kinase. *Circulation* 116:2809-2817, 2007.

190. Sato H, **Bolli R**, Rokosh G, Bi Q, Dai S, Shirk G, Tang XL. The cardioprotection of the late phase of ischemic preconditioning is enhanced by postconditioning via a COX-2 mediated mechanism in conscious rats. *Am J Physiol* 293:H2557-2564, 2007.
191. Bearzi C, Rota M, Hosoda T, Tillmanns J, Nascimbene A, DeAngelis A, Yasuzawa-Amano S, Trofimova L, Siggins RW, Lecapitaine N, Cascapera S, Beltrami A, D'Alessandro DA, Quaini Z, Urbanek K, Michler R, **Bolli R**, Kajstura J, Leri A, Anversa P. Human cardiac stem cells. *Proc Nat Acad Sci* 104(35):14068-73, 2007.
192. Rota M, Kajstura J, Hosoda T, Bearzi C, Vitale S, Esposito G, Iaffaldano G, Padin-Iruegas ME, Gonzalez A, Rizzi R, Small N, Muraski J, Alvarez R, Chen X, Urbanek K, **Bolli R**, Houser SR, Leri A, Sussman MA, Anversa P. Bone marrow cells adopt the cardiomyogenic fate *in vivo*. *Proc Nat Acad Sci* 104:17783-8, 2007.

2008

193. Zuba-Surma E, Kucia M, Dawn B, Guo Y, Ratajczak M, **Bolli R**. Bone marrow-derived pluripotent very small embryonic-like stem cells (VSELs) are mobilized after acute myocardial infarction. *J Mol Cell Cardiol* 44:865-873, 2008.
194. Guo Y, Li Q, Wu W, Tan W, Zhu X, Mu J, **Bolli R**. Endothelial nitric oxide synthase is not necessary for the early phase of ischemic preconditioning in the mouse. *J Mol Cell Cardiol* 44:496-501, 2008.
195. Huang Y, Ratajczak M, Reza R, Xu H, Tanner M, Rezzoug F, Hussain L, Fugier-Vivier I, **Bolli R**, Ildstad S. Flt3 expression discriminates HSC subpopulations with differing engraftment-potential: identifying the most potent combination. *Transplantation* 85:1175-1184, 2008.
196. Gonzalez A, Rota M, Nurzynska D, Misao Y, Tillmanns J, Ojaimi C, Padin-Iruegas M, Muller P, Esposito G, Bearzi C, Vitale S, Dawn B, Math S, Baker M, Hintze T, **Bolli R**, Urbanek K, Hosoda T, Anversa P, Kajstura J, Leri A. Activation of cardiac progenitor cells reverses the failing heart senescent phenotype and prolongs lifespan. *Circ Res* 102:597-606, 2008.
197. Tillmanns J, Rota M, Hosoda T, Amano K, Yasuzawa-Amano S, Misao Y, LeCapitaine N, Esposito G, Siggins RW, DeAngelis A, Loredi M, Vitale S, Bearzi C, **Bolli R**, Urbanek K, Leri A, Kajstura J, Anversa P. Formation of large coronary arteries by cardiac stem cells: A biological bypass. *Proc Natl Acad Sci USA* 105:1668-1673, 2008.
198. Mentzer, Jr. R, Bartels C, **Bolli R**, Boyce S, Buckberg, G, Chaitman B, Haverich A, Knight J, Menasche P, Myers ML, Nicolau J, Simoons M, Thulin L, Weisel R. Sodium-hydrogen exchange inhibition by cariporide to reduce the risk of ischemic cardiac events in patients undergoing coronary artery bypass grafting: results of the EXPEDITION study. *J Thor Cardiovasc Surg* 85:1261-1270, 2008.
199. Abdel-Latif A, Zuba-Surma EK, Case J, Tiwari S, Hunt G, Ranjan S, Vincent RJ, Srouf EF, **Bolli R**, Dawn B. TGF- β 1 enhances cardiomyogenic differentiation of skeletal muscle-derived adult primitive cells. *Basic Res Cardiol* 103:514-524, 2008.
200. Wang G, Guo Y, Vondriska T, Zhang J, Zhang S, Tsai L, Zong N, **Bolli R**, Bhatnagar A, Prabhu S. Acrolein consumption exacerbates myocardial ischemic injury and blocks nitric oxide-induced PKC ϵ signaling and cardioprotection. *J Mol Cell Cardiol* 44:1016-1022, 2008.
201. Shinmura K, Nagai M, Tamaki K, **Bolli R**. Loss of ischemic preconditioning in ovariectomized rat hearts: possible involvement of impaired PKC ϵ phosphorylation. *Cardiovasc Res* 79:387-394, 2008.
202. Flaherty MP, Abdel-Latif A, Li Q, Hunt G, Ranjan S, Ou Q, Tang XL, Johnson RK, **Bolli R**, Dawn B. Noncanonical Wnt11 signaling is sufficient to induce cardiomyogenic differentiation in unfractionated bone marrow mononuclear cells. *Circulation* 117:2241-2252, 2008.
203. Abdel-Latif A, **Bolli R**, Zuba-Surma EK, Tleyjeh IM, Hornung CA, Dawn B. G-CSF Therapy for cardiac repair after acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials. *Am Heart J* 156:216-226, 2008.
204. Dawn B, Tiwari S, Kucia M, Zuba-Surma, EK, Guo Y, SanganalMath SK, Abdel-Latif A, Hunt G, Vincent RJ, Taher H, Reed N, Ratajczak M, **Bolli R**. Transplantation of bone marrow –derived very small embryonic-like stem cells (VSELs) attenuates left ventricular dysfunction and remodeling after myocardial infarction. *Stem Cells* 26:1646-1655, 2008.

205. Shinmura K, Tamaki K, **Bolli R**. Impact of 6-month caloric restriction on myocardial ischemic tolerance: possible involvement of nitric oxide-dependent increase in nuclear Sirt1. *Am J Physiol* 295:H2348-H2355, 2008.
206. Rota M, Padin-Iruegas M, Misao Y, De Angelis A, Maestroni S, Ferreira-Martins J, Fiumana E, Rastaldo R, Arcarese M, Mitchell T, Boni A, **Bolli R**, Urbanek K, Hosoda T, Anversa P, Leri A, Kajstura J. Local activation or implantation of cardiac progenitor cells rescues scarred infarcted myocardium improving cardiac function. *Circ Res* 103:107-116, 2008.
207. Wang G, Partridge C, Xiang X, Gu Y, Ortines R, Kingery J, Li Q, Rokosh G, Ford R, Spinale F, Srivastava S, Xuan Y, Bhatnagar A, **Bolli R**, Prabhu S. Cardioprotective and anti-apoptotic role of heme oxygenase-1 in the failing heart. (Submitted)
208. West M, Rokosh G, Obal D, Velayutham M, Xuan Y, Hill B, Keith R, Schrader J, Guo Y, Conklin D, Prabhu S, Zweier J, **Bolli R**, Bhatnagar A. Cardiac myocyte-specific expression of inducible nitric oxide synthase protects against ischemia/reperfusion injury by preventing mitochondrial permeability transition. *Circulation* 118:1970-1978, 2008.
209. Flaherty M, Guo Y, Tiwari S, Rezazadeh A, Hunt G, Tang XL, **Bolli R**, Dawn B. The role of TNF- α receptors p55 and p75 in acute myocardial ischemia/reperfusion injury and late preconditioning. *J Mol Cell Cardiol* 45:735-41, 2008.
210. Boni A, Urbanek K, Nascimbene A, Hosoda T, Zheng H, Delucchi F, Amano K, Gonzalez A, Vitale S, Ojaimi C, Rizzi R, **Bolli R**, Yutzey K, Rota M, Kajstura J, Anversa P, Leri A. Notch 1 regulates the fate of cardiac progenitor cells. *Proc Nat Acad Sci* 105:15529-34, 2008.

2009

211. SanganalMath SK, Stein AB, Guo Y, Tiwari S, Hunt G, Vincent RJ, Huang Y, Rezazadeh A, Ildstad ST, Dawn B, **Bolli R**. The beneficial effects of postinfarct cytokine combination therapy are sustained during long-term follow-up. *J Mol Cell Cardiol* (In Press).
212. Li Q, Guo Y, Ou Q, Cui C, Wu WJ, Tan W, Zhu X, Lanceta L, SanganalMath SK, Dawn B, Shinmura K, Rokosh G, Wang S, **Bolli R**. Gene transfer of inducible nitric oxide synthase affords cardioprotection by upregulating heme oxygenase-1 via an NF-kappaB-dependent pathway. *Circulation* (In Press).
213. Zuba-Surma E, Guo Y, Taher H, SanganalMath S, Hunt G, Vincent R, Kucia M, Abdel-Latif A, Ratajczak M, Dawn B, **Bolli R**. Transplantation of expanded bone marrow-derived very small embryonic-like stem cells (VSEL-SCs) improves left ventricular function and remodeling after myocardial infarction. *J Cellular Mol Med* (Submitted)

Publications: (ii) CASE REPORTS

1. Heibig J, **Bolli R**, Harris S. Initial coronary occlusion improves tolerance to subsequent prolonged balloon inflations. *Catheterization and Cardiovascular Diagnosis* 16:99-102, 1989.
2. O'Neill PG, Rajan N, Charlat ML, **Bolli R**. Captopril-related exfoliative dermatitis. *Texas Medicine* 85:40-41, 1989.

Publications: (iii) REVIEWS

(*Reviews cited more than 100 times are marked with an asterisk.)

1976

1. **Bolli R**. Surgical treatment of the complications of acute myocardial infarction (M.D. Thesis). University of Perugia Medical School, 1976. (Original title: Trattamento chirurgico delle complicazioni dell'infarto miocardico acuto).

1982

2. **Bolli R**. Protection of ischemic myocardium in experimental animals and in man: A review. *Cardiovasc Res Ctr Bull* 21:1-33, 1982.

1986

3. **Bolli R**, Gotto AM. Coronary bypass surgery: When should it be recommended? *Heartbeat* 4:8-10, 1986.

1987

4. **Bolli R.** Bypass surgery in patients with coronary artery disease: Indications based on the multicenter randomized trials. *Chest* 91:760-764, 1987.

1988

- *5. **Bolli R.** Oxygen-derived free radicals and postischemic myocardial dysfunction ("stunned myocardium"). *J Am Coll Cardiol* 12:239-249, 1988. **Citations: 299**

1989

6. **Bolli R, Triana JF, Jeroudi MO.** Postischemic mechanical and vascular dysfunction (myocardial "stunning" and microvascular "stunning") and the effects of calcium channel blockers on ischemia/reperfusion injury. *Clin Cardiol* 12:III-16-III-25, 1989.

1990

7. **Bolli R, McCay PB.** Use of spin traps in intact animals undergoing myocardial ischemia/reperfusion: A new approach to assessing the role of oxygen radicals in myocardial "stunning". *Free Rad Res Comms* 9:169-180, 1990.

8. **Bolli R, Triana JF, Unisa A, Heibig J.** Role of oxy-radicals in myocardial ischemia/reperfusion injury. *Consultant* 30 (No. 5, Suppl):12-22, 1990.

- *9. **Bolli R.** Mechanism of myocardial "stunning." *Circulation* 82:723-738, 1990. **Citations: 774**

1991

- *10. **Bolli R.** Oxygen-derived free radicals and myocardial reperfusion injury: An overview. *Cardiovasc Drugs Ther* 5:249-268, 1991. **Citations: 217**

11. Hearse DJ, **Bolli R.** Reperfusion-induced injury: Manifestations, mechanisms and clinical relevance. *Trends Cardiovasc Med* 1:233-240, 1991. **Citations: 175**

12. **Bolli R, Hartley CJ, Rabinovitz RS.** Clinical relevance of myocardial "stunning." *Cardiovasc Drugs Ther* 5:877-890, 1991.

1992

- *13. Hearse DJ, **Bolli R.** Reperfusion-induced injury: Manifestations, mechanisms, and clinical relevance. *Cardiovasc Res* 26:101-108, 1992. **Citations: 196**

- *14. **Bolli R.** Myocardial "stunning" in man. *Circulation* 86:1671-1691, 1992. **Citations: 397**

1994

- *15. Jeroudi MO, Hartley CJ, **Bolli R.** Myocardial reperfusion injury: Role of oxygen radicals and potential therapy with antioxidants. *Am J Cardiol* 73:2B-7B, 1994. **Citations: 101**

16. Zughuib ME, Tang XL, Sun JZ, **Bolli R.** Myocardial reperfusion injury: Fact or myth? A 1993 appraisal of a seemingly endless controversy. *Annals of the New York Academy of Sciences* 723:218-228, 1994.

17. **Bolli R.** Myocardial ischemia: Metabolic disorders leading to cell death. *Rev Port Cardiol* 13:649-653, 1994.

1996

18. **Bolli R.** Myocardial "stunning" 20 years later: A summary of current concepts regarding its pathophysiology, pathogenesis, and clinical significance. *Dialogues in Cardiovascular Medicine* 1:5-26, 1996.

1998

- *19. Kloner RA, **Bolli R, Marban E, Braunwald E, Reinlib L.** Medical and cellular implications of stunning, hibernation and preconditioning: An NHLBI workshop. *Circulation* 97:1848-1867, 1998. **Citations: 271**

20. **Bolli R.** Basic and clinical aspects of myocardial stunning. *Progr Cardiovasc Dis* 40:477-516, 1998.

- *21. **Bolli R, Dawn B, Tang X-L, Qiu Y, Ping P, Xuan Y-T, Jones WK, Takano H, Guo Y, Zhang J.** The nitric oxide hypothesis of late preconditioning. *Basic Res Cardiol* 93:325-338, 1998. **Citations: 170**

1999

- *22. **Bolli R**, Marban E. Molecular and cellular mechanisms of myocardial stunning. *Physiol Reviews* 79:609-634, 1999. **Citations: 419**
23. **Bolli R**, Dawn B, Tang X-L. Myocardial stunning. *Medicographia* 21:156-157, 1999.
24. Bhatnagar A, **Bolli R**. Modulation of K_{ATP} channels to protect the ischemic myocardium: Clinical implications. *Exp Clin Cardiol* 4:20-22, 1999.

2000

- *25. **Bolli R**. The late phase of preconditioning. *Circ Res* 87:972-983, 2000. **Citations: 378**

2001

- *26. **Bolli R**. Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: An overview of a decade of research. *J Mol Cell Cardiol* 33:1897-1918, 2001. **Citations: 271**

2002

- *27. **Bolli R**, Shinmura K, Tang XL, Kodani E, Xuan YT, Guo Y, Dawn B. Discovery of a new function of cyclooxygenase (COX-2): COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. *Cardiovasc Res* 55:506, 2002. **Citations 106**

2003

28. **Bolli R**, Dawn B, Xuan Y-T. Role of the JAK-STAT pathway in protection against myocardial ischemia/reperfusion injury. *Trends Cardiovasc Med* 13:72-79, 2003.
29. **Bolli R**. The role of sodium-hydrogen ion exchange in patients undergoing coronary artery bypass grafting. *J Card Surg* 18:21-26, 2003.

2004

30. Hensley K, Benaksas EJ, **Bolli R**, Comp P, Mou S, Pye QN, Stoddard MF, Williamson KS, West M, Wechter WJ, Floyd RA. New perspectives on vitamin E: Gamma tocopherol and carboxyethylhydroxychroman (CEHC) metabolites in biology and medicine. *Free Rad Biol Med* 36:1-15, 2004.
31. Anversa P, Sussman MA, **Bolli R**. Molecular genetic advances in cardiovascular medicine: Focus on the myocyte. *Circulation* 109:2832-2838, 2004.
- *32. **Bolli R**, Becker L, Gross G, Mentzer R Jr, Balshaw D, and Lathrop DA. Myocardial protection at a crossroads: The need for translation into clinical therapy. *Circ Res* 95:125-134, 2004. **Citations 126**
33. Stein AB, Yang XL, Guo Y, Xuan YT, Dawn B, **Bolli R**. Delayed adaptation of the heart to stress: Late preconditioning. *Stroke* 35:2676-2679, 2004.

2005

34. Dawn B, **Bolli R**. Adult bone marrow-derived stem cells: Regenerative potential, plasticity, and tissue commitment. *Bas Res Cardiol* 100:494-503, 2005.
35. Anversa P, Rota M, Urbanek K, Hosoda T, Sonnenblick EH, Leri A, Kajstura J, **Bolli R**. Myocardial aging: A stem cell problem. *Bas Res Cardiol* 100:482-493, 2005.
36. Kajstura J, **Bolli R**, Sonnenblick E, Anversa P, Leri A. Apoptosis, a nice way to die. *J Mol Cell Cardiol* 2005 (in press)
37. Jneid H, Leeser M, **Bolli R**. Cardiac preconditioning during percutaneous coronary interventions. A post-hoc analysis and literature review. *Cardiovasc Drugs Ther* 19:211-217, 2005.
38. Dawn B, Zuba-Surma E, Abdel-Latif A, Tiwari S, **Bolli R**. Cardiac stem cell therapy for myocardial regeneration: A clinical perspective. *Minerva Cardioangiol* 53:549-564, 2005.

2006

39. Jones SP, **Bolli R**. The ubiquitous role of nitric oxide in cardioprotection. *J Mol Cell Cardiol* 40:16-23, 2006. **Citations 112**

40. Kajstura J, Rota M, Urbanek K, Hosoda T, Bearzi C, Anversa P, **Bolli R**, Leri A. The telomere-telomerase axis and the heart. *Antioxidants and Redox Signaling* 8(11-12):2125-41, 2006.
41. **Bolli R**. Preconditioning: A paradigm shift in the biology of myocardial ischemia. *Am J Physiol* 292(1):H19-27, 2007.
42. Anversa P, Leri A, Rota M, Bearzi C, Urbanek K, Kajstura J, **Bolli R**. Stem cells, myocardial regeneration and methodological artifacts. *Stem Cells* 3:589-601, 2007.

2007

43. **Bolli R**, Li QH, Tang XL, Guo Y, Xuan YT, Rokosh G, Dawn B. The late phase of preconditioning and its natural clinical application - gene therapy. *Heart Failure Reviews* 12(3-4):189 - 199, 2007.
44. Anversa P, Leri A, Rota M, Hosoda T, Bearzi C, Urbanek K, Kajstura J, **Bolli R**. Concise review: stem cells, myocardial regeneration, and methodological artifacts. *Stem Cells* 25(3):589-601, 2007.

2008

45. Kajstura J, Urbanek K, Rota M, Bearzi C, Hosoda T, **Bolli R**, Anversa P, Leri A. Cardiac stem cells and myocardial disease. *J Mol Cell Cardiol* 45:505-513, 2008.

2009

46. Chamuleau S, Vrijssen K, Rokosh G, Tang XL, Piek J, **Bolli R**. Cell therapy for ischemic heart disease: focus on the role of resident cardiac stem cells. *Netherlands Heart J* 17(5):199-207, 2009.

Publications: (iv) EDITORIALS

1989

1. **Bolli R**. Potential role of serotonin in dynamic coronary stenosis. *J Am Coll Cardiol* 14:460-461, 1989.

1991

2. Zoghbi WA, **Bolli R**. The increasing complexity of assessing diastolic function from ventricular filling dynamics. *J Am Coll Cardiol* 17:237-238, 1991.
3. **Bolli R**. Superoxide dismutase 10 years later: A drug in search of a use. *J Am Coll Cardiol* 18:231-233, 1991.

1992

4. Lewandowski ED, **Bolli R**. Magnetization transfer as a technique for *in vivo* assessment of altered energy transfer in cardiac hypertrophy. *J Am Coll Cardiol* 19:229-231, 1992.

1993

5. **Bolli R**. Comments to the article "Understanding the jargon: a glossary of terms used (and misused) in the study of ischaemia and reperfusion." *Cardiovasc Res* 27:170-171, 1993.
6. **Bolli R**. Role of neutrophils in myocardial stunning after brief ischaemia: The end of a six-year-old controversy (1987-1993). *Cardiovasc Res* 27:728-730, 1993.

1995

7. **Bolli R**. Common methodological problems and artifacts associated with studies of myocardial stunning *in vivo*. *Basic Res Cardiol* 90:257-262, 1995.

1996

8. **Bolli R**. The early and late phases of preconditioning against myocardial stunning and the essential role of oxyradicals in the late phase: An overview. *Basic Res Cardiol* 91:57-63, 1996.

1997

9. **Bolli R**. Does lethal myocardial reperfusion injury exist? A controversy that is unlikely to be settled in our lifetime. *J Thromb Thrombolysis* 4:109-110, 1997.

1998

10. **Bolli R**. Why myocardial stunning is clinically important. *Basic Res Cardiol* 93:169-172, 1998.

11. **Bolli R.** Causative role of oxyradicals in myocardial stunning: A proven hypothesis. A brief review of the evidence demonstrating a major role of reactive oxygen species in several forms of postischemic dysfunction. *Basic Res Cardiol* 93:156-162, 1998.

12. Auchampach JA, **Bolli R**, Zhang Q. Editorial comment to the article "Optimal myocardial preconditioning in a human model of ischemia and reperfusion". *Circulation* 98:II-194–II 196, 1998

1999

13. Auchampach JA, **Bolli R.** Adenosine receptor subtypes in the heart: therapeutic opportunities and challenges. *Am J Physiol* 45:H1113-H1116, 1999.

14. Marbán E, **Bolli R**, Breitwieser G, Busse R, Dietz H, Endoh M, Finkel T, Kass D, Lowenstein C, Rabinovitch M, Tomaselli G. The evolutionary process, and the process of evolution. *Circ Res* 85:303, 1999.

2000

15. Marbán E, **Bolli R**, Breitwieser G, Busse RFE, Dietz HC, Endoh M, Finkel T, Kass DA, Lowenstein C, Rabinovitch M, Tomaselli GF. Under new management: A six-month progress report on *Circulation Research*. *Circ Res* 86:111-113, 2000.

16. Marbán E, **Bolli R**, Breitwieser G, Busse RFE, Dietz HC, Endoh M, Finkel T, Kass DA, Lowenstein C, Rabinovitch M, Tomaselli GT. Interactive modeling adds a new dimension to scientific publishing. *Circ Res* 87:955, 2000.

17. Marbán E, **Bolli R**, Breitwieser G, Busse RFE, Dietz HC, Endoh M, Finkel T, Kass DA, Lowenstein C, Rabinovitch M, Tomaselli GT. *Circulation Research* Editors' Yearly Report: 1999–2000. *Circ Res* 87:261-263, 2000.

2001

18. Dawn B, **Bolli R.** Toward a better understanding of the metabolic effects of ischemic preconditioning in humans. *J Cardiothorac Vasc Anesth* 15:409-411, 2001.

19. **Bolli R**, Dawn B, Xuan Y-T. Emerging role of the JAK-STAT pathway as a mechanism of protection against ischemia/reperfusion injury. *J Mol Cell Cardiol* 33:1893-1896, 2001.

2002

20. **Bolli R.** Regeneration of the human heart -- No chimera? *N Engl J Med* 346:55-56, 2002.

2004

21. Jneid, Hani, **Bolli, R.** Inotrope use at separation from cardiopulmonary bypass and the role of pre-bypass TEE. *J Cardiothorac Vasc Anesth* 18:401-403, 2004.

22. Dawn B, **Bolli R.** Bone marrow cells for cardiac regeneration: the quest for the protagonist continues. *Cardiovasc Res* 65:293-295, 2004.

2005

23. **Bolli R**, Jneid H, Dawn B. Bone marrow cell-mediated cardiac regeneration: A veritable revolution. *J Am Coll Cardiol* 46:1659-1661, 2005.

24. **Bolli R**, Dawn B. HO-1 induction by HIF-1: A new mechanism for delayed cardioprotection. *Am J Physiol* 2005 289:H522-H524, 2005.

26. **Bolli R**, Abdel-Latif A. No pain, no gain: The useful function of angina. *Circulation* 112:3541-3543, 2005.

27. **Bolli R.** Introduction to Focused Issue on cardiac repair by stem cells. *Basic Res Cardiol* 100:494-503, 2005.

2006

28. Kajstura J, Leri A, **Bolli R**, Anversa P. Endothelial progenitor cells: Neovascularization or more? *J Mol Cell Cardiol* 40:1-9, 2006.

29. Dawn B, **Bolli R.** Increasing evidence that estrogen is an important modulator of bone marrow-mediated cardiac repair after acute infarction. *Circulation* 114:2203-2205, 2006.

2007

30. Dawn B, **Bolli R.** Bone-marrow for cardiac repair: the importance of characterizing the phenotype and function of injected cells. *Eur Heart J* 28(6):651-652, 2007.

2008

31. Dawn B, **Bolli R**. Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation, potential implications for COX-2 inhibition. *Circ Res* (In Press)
32. Dawn, B, **Bolli R**. Mutation in the prostacyclin receptor, cardiovascular disease, and coxibs. American Heart Association Learning Library. <http://pt.wkhealth.com/pt/re/aha/commentarytoc.htm>; published online May 12, 2008.

2009

33. **Bolli R**, Dawn B. The cornucopia of "pleiotropic" actions of statins: myogenesis as a new mechanism for statin-Induced benefits. *Circ Res* 104:144-146.

Publications: (v) LETTERS

1995

1. Galli M, Marcassa C, **Bolli R**. Spontaneous delayed recovery of perfusion and contraction after anterior infarction. *Circulation* 91:1612-1613, 1995.
2. Galli M, Marcassa C, **Bolli R**. Temporal changes in myocardial perfusion patterns after anterior infarction. *Circulation* 92:2757-2758, 1995.

1997

3. **Bolli R**, Leesar MA, Stoddard M. Ischemic preconditioning during coronary angioplasty. *J Am Coll Cardiol* 29:469, 1997.

1998

4. Response to letter to the Editor "Adenosine Pretreatment of Human Myocardium and Ischemic Preconditioning" by Lee. *Circulation* 97:2279, 1998.
5. **Bolli R**, Leesar MA, Ahmed M, Stoddard M, Broadbent J. Letter to the Editor. *Circulation* 98:824-825.

2003

6. **Bolli R**. Response to letter to the Editor "Cyclooxygenase-2 in Myocardial Ischemia: Is it Really a Friend?" by Abbate et al. *J Am Coll Cardiol* 42:1714-1715, 2003.

2005

7. Shinmura K, **Bolli R**. The risk of myocardial infarction with COX-2 inhibitors. *Ann Int Med* 143:615-618, 2005.

Publications: (vi) BOOK CHAPTERS

1981

1. Goldstein RE, Davenport NJ, **Bolli R**, Capurro N, Bonow RO, Epstein SE. Effects of aspirin and sulfinpyrazone on coronary collateral blood flow and myocardial infarct size after acute coronary occlusion in the dog. In: *Effects of Platelet-Active Drugs on the Cardiovascular System*. Hirsh J, Steele PP, Verrier RL, Eds., Denver, University of Colorado Health Science Center, pp. 55-69, 1981.

1988

2. **Bolli R**, Roberts R. Role of oxy-radicals in postischemic myocardial dysfunction. In: *Oxygen Radicals in the Pathophysiology of Heart Disease*. Singal PK, Ed. Boston, Kluwer Academic Publishers, pp. 203-225, 1988.

1990

3. Patel B, Jeroudi MO, **Bolli R**. Pathogenesis of ischemic myocardial injury and methods for myocardial protection. In: *The Science and Practice of Pediatric Cardiology*. Garson A, Jr, Bricker JT, McNamara DG, Eds. Philadelphia, Lea & Febiger, pp. 266-279, 1990.
4. **Bolli R**, Patel BS, Jeroudi MO, Lai EK, McCay PB. Evidence for free radical generation *in vivo* during cardiac ischemia and reperfusion. In: *Proceedings of the NATO Advanced Research Workshop on "Action of Free Radicals and Active Forms of Oxygen on Lipoproteins and Membrane Lipids: Cellular Interaction and Atherogenesis."* New York, Plenum Press, pp. 89-97, 1990.

1991

5. Li XY, Jeroudi MO, Zughuib M, Sekili S, Sun JZ, **Bolli R.** Stunned and hibernating myocardium: Pathophysiology, pathogenesis, and clinical implications. In: *Left Ventricular Dysfunction in Stunned and Hibernating Myocardium*. Buller N, Henderson AH, Krayenbul HP, Eds. Amsterdam, Excerpta Medica, pp. 6-18, 1991.
6. Li XY, Jeroudi MO, **Bolli R.** Myocardial function and metabolism in the experimental model of coronary occlusion and reperfusion. In: *Myocardial Ischemia, Hibernation and Stunning*. Fazzini PF, Parodi O, Eds. Firenze (Italy), O.I.C. Medical Press, pp. 49-78, 1991.

1992

7. **Bolli R.** Postischemic myocardial "stunning": Pathogenesis, pathophysiology, and clinical relevance. In: *Myocardial Protection: The Pathophysiology of Reperfusion and Reperfusion Injury*. Yellon DM, Jennings RB, Eds. New York, Raven Press, pp. 105-149, 1992.
8. **Bolli R,** Hartley CJ, Rabinovitz RS. Clinical relevance of myocardial "stunning." In: *Stunning, Hibernation, and Calcium in Myocardial Ischemia and Reperfusion*. Opie LH, Ed. Boston, Kluwer Academic Publishers, pp. 56-82, 1992.
9. Li XY, Zughuib ME, Jeroudi MO, Hartley C, Sun JZ, Sekili S, **Bolli R.** Postischemic myocardial dysfunction (myocardial "stunning"): Role of oxidative stress. In: *New Aspects in the Treatment of Failing Heart*. Yasuda H, Kawaguchi H, Eds. Tokyo, Springer-Verlag, pp. 3-7, 1992.

1993

10. **Bolli R.** Role of oxygen radicals in myocardial stunning. In: *Stunned Myocardium: Properties, Mechanisms, and Clinical Manifestations*. Kloner RA, Przyklenk K, Eds. New York, Marcel Dekker, pp. 155-195, 1993.
11. Zughuib M, Li XY, Jeroudi MO, Hartley CJ, **Bolli R.** Oxidative stress in the pathogenesis of postischemic ventricular dysfunction (myocardial "stunning"). In: *Oxygen Free Radicals in Tissue Damage*. Tarr M, Samson F, Eds. Boston, Birkhauser, pp. 211-249, 1993.
12. Zughuib ME, McCay PB, Jeroudi MO, Hartley C, Sun JZ, Sekili S, Li XY, **Bolli R.** Moderate ischemic injury and myocardial stunning. In: *Ischemia-reperfusion in Cardiac Surgery*. Piper HM, Preusse CJ, Eds. Dordrecht, Kluwer Academic Publishers, pp. 3-40, 1993.
13. Hartley CJ, Rabinovitz RS, Noon GP, **Bolli R,** Chelly JE. Prospects for functional echocardiography. In: *Frontiers in Cardiovascular Imaging*. Zaret BL, Kaufman L, Berson AS, Dunn RA, Eds. New York, Raven Press, pp. 237-248, 1993.
14. Zughuib ME, Sun JZ, **Bolli R.** Effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury: An overview. In: *Angiotensin and the Heart*. Grobecker H, Heusch G, Strauer BE, Eds. New York, Springer-Verlag, pp. 155-167, 1993.

1996

15. Jeroudi MO, Tang XL, Abd-Elfattah AS, **Bolli R.** Effect of adenosine on myocardial stunning. In: *Purines and Myocardial Protection*. Abd-Elfattah AS, Wechsler AS, Eds. Boston, Kluwer Academic Publishers, pp. 297-313, 1996.

1997

16. Stoddard M, **Bolli R.** "Stunned" myocardium in the clinical setting: Occurrence, diagnosis and treatment. In: *New Ischemic Syndromes: Beyond Angina and Infarction*. Yellon DM, Rahimtoola SH, Opie LH, Eds. Authors' Publishing House, pp. 158-191, 1997.
17. **Bolli R.** Oxyradicals in the pathogenesis of myocardial stunning. In: *Intrinsic Adaptive Mechanisms During Ischemia and Reperfusion: Preconditioning, Stunning, Hibernation*. Heyndrickx GR, Vatner SF, Wijns W, Eds. Raven Publishing Company, pp. 205-228, 1997.
18. **Bolli R,** Tang XL, Qiu Y, Park SW. The late phase of preconditioning against myocardial stunning. In: *Adenosine, Cardioprotection and Its Clinical Application*. Mentzer RM, Kitakaze M, Downey JM, Hori M, Eds. Kluwer Academic Publishers, pp. 29-35, 1997.

1998

19. **Bolli R**, Dawn B, Tang X-L, Qiu Y, Ping P, Zhang J, Takano H. Delayed preconditioning against myocardial stunning: Role of nitric oxide as trigger and mediator. In: Delayed Preconditioning and Adaptive Cardioprotection. Yellon DM, Baxter GF, Eds. Kluwer Academic Publishers, pp. 29-46, 1998.

2002

20. Dawn B, **Bolli R**. Role of nitric oxide in myocardial preconditioning. In: Nitric Oxide: Novel Actions, Deleterious Effects and Clinical Potential. Chiueh CC, Hong J-S, Leong SK, Eds. The New York Academy of Sciences, pp. 19-41, 2002.

2006

21. **Bolli R**, Anversa P. Stem cells and cardiac aging. In: Cardiac Regeneration and Stem Cell Therapy. (In press).

Publications: (vii) PROCEEDINGS OF MEETINGS

1. Tang XL, Park SW, Qiu Y, Sun JZ, **Bolli R**. Myocardial reperfusion injury and oxygen free radicals. Research and Clinical Forums 17:35-42, 1995.
2. **Bolli R**. Introduction to "New approaches to myocardial protection". J Card Surg 18:1-2, 2003.

Scientific Conferences Organized:

- Organizer of the Scientific Conference of the Council on Circulation of the AHA "Vascular and Myocardial Aspects of Ischemic Heart Disease", Lake Tahoe, NV, February 22-25, 1998.
- Organizer and Chairman of the XXII Annual Sessions of the American Section of the ISHR, Louisville, KY, June 14-18, 2000.
- Co-organizer of the NIH Workshop on Post-Resuscitative and Initial Utility in Life Saving Efforts (PULSE), Leesburg, VA, June 29-30, 2000.
- Scientific Program Advisory Committee for the XVI World Congress of the ISHR, May 1998.
- International Corporate Sponsorship Committee for the XVI World Congress of the ISHR, May 1998.
- Scientific Program Committee for the Second International Conference on the Pathophysiology of Stunning, Hibernation and Preconditioning, October 1998.
- International Advisory Board for the XVII World Congress of the ISHR, July 2001.
- Organizing Committee, Scientific Conference of the AHA "Molecular, Integrative, and Clinical Approaches to Myocardial Ischemia", Seattle, WA, August 9-11, 2001.
- Program Committee, Scientific Conference of the AHA "Advances in the Molecular and Cellular Mechanisms of Heart Failure", Snowbird, UT, August 21-25, 2002.
- Committee on Scientific Sessions Program (at-large member), 2002-2005.
- Scientific Advisory Committee for the XXV Annual Sessions of the North American Section of the ISHR, Mystic, CT, June 28 - July 1, 2003.
- Organizer and Chairman of the NHLBI Workshop on Translation of Therapies for Protecting the Heart from Ischemia, Bethesda, MD, June 23-24, 2003.
- Program Committee, Scientific Conference of the AHA "Molecular Mechanisms of Growth, Death, and Regeneration in the Myocardium", Snowbird, UT, August 13-17, 2003.
- Scientific Program Advisory Committee for the XVIII World Congress of the ISHR, August 2004.
- Scientific Program Advisory Committee for the XIX World Congress of the ISHR, June 2007.
- Co-organizer and Co-chair, Third Annual Symposium of the Council on Basic Cardiovascular Sciences of the AHA, Keystone, CO, July 31-August 3, 2006.
- Co-organizer and Co-director, Cardiovascular Revascularization Therapy 2007, Washington, D.C., March 6-8, 2007.
- Co-organizer and Co-director, Cardiovascular Revascularization Therapy 2008, Washington, D.C., February 11-13, 2008.
- Scientific Advisory Committee for the XXX Annual Sessions of the North American Section of the ISHR, Cincinnati, OH, June 17-20, 2008
- Scientific Program Advisory Committee for the XX World Congress of the ISHR, May 2010.

Invited Lectures: Total of 220 extramural lectures.